var title_f35_13_36048="Carbuncle";
var content_f35_13_36048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Carbuncle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carbuncle, which is a series of abscesses in the subcutaneous tissue that drain via hair follicles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36048=[""].join("\n");
var outline_f35_13_36048=null;
var title_f35_13_36049="Patient information: Bedbugs (The Basics)";
var content_f35_13_36049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15346\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/1/20500\">",
"         Bedbugs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/30/14817\">",
"         Patient information: Bedbugs (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bedbugs (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bedbugs-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H46118747\">",
"      <span class=\"h1\">",
"       What are bedbugs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bedbugs are tiny bugs that do not fly (",
"      <a class=\"graphic graphic_picture graphicRef66540 \" href=\"mobipreview.htm?20/1/20500\">",
"       picture 1",
"      </a>",
"      ). They are found all over the world. Bedbugs can live in hotels, houses, and other places where people rest and sleep. They can live in your mattress, your clothes, the walls, and other parts of your house. Most often, they bite you while you are sleeping or resting.",
"     </p>",
"     <p>",
"      If you have bedbugs in your home, you may not be able to see them. They are very small and hide during the day.",
"     </p>",
"     <p>",
"      Bedbugs do not spread diseases in people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46118754\">",
"      <span class=\"h1\">",
"       What do bedbug bites look like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bedbug bites are small, red and swollen areas of the skin that are often:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        In a row or a line",
"       </li>",
"       <li>",
"        On parts of the body not usually covered by clothes, such as the face, neck, arms, and hands",
"       </li>",
"       <li>",
"        Very itchy",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most people don&rsquo;t feel it when they get bitten. They may notice the bites in the morning or after a day or two. Bedbug bites can take 3 to 6 weeks to heal. They can get infected if you scratch them a lot.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46118761\">",
"      <span class=\"h1\">",
"       Is there a test to tell if I have bedbug bites?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse may suspect that your bites are from bedbugs when he or she looks at your skin. Other types of bugs and some diseases can also cause red bumps on the skin that look like bedbug bites.",
"     </p>",
"     <p>",
"      The only way to know for sure if you have bedbugs in your home is to catch one. Experts can then inspect the insect. They can tell if it is a bedbug or another type of bug.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46118768\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to help my bites feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help your bites feel better and heal faster, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep the skin clean and dry",
"       </li>",
"       <li>",
"        Try not to scratch the bites",
"       </li>",
"       <li>",
"        Use an anti-itch lotion or cream to help with the itching",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46118775\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if the bites:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get redder",
"       </li>",
"       <li>",
"        Get more swollen",
"       </li>",
"       <li>",
"        Start having pus come out of them",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If any of these things happen, your bites may be infected. Your doctor or nurse may prescribe a special medicine to put on your bites.",
"     </p>",
"     <p>",
"      When you first find out you have bedbugs in your home, you may feel very worried or upset. If you feel this way, talk to your doctor about what you can do.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46118782\">",
"      <span class=\"h1\">",
"       What should I do about the bedbugs in my home?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will need to get rid of the bedbugs in your home so you do not get any more bites. To start, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vacuum your home",
"       </li>",
"       <li>",
"        Wash your clothes and bedding, and dry them in a dryer that is on the hottest setting",
"       </li>",
"       <li>",
"        Clean up your home",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Then, you or your landlord should call a pest control service. The workers might use a chemical in your home to get rid of the bedbugs. You should not try to use any chemicals yourself.",
"     </p>",
"     <p>",
"      If you want to get rid of some of your clothes or things, do not give them to other people. The bedbugs could still be in them. You do not want to spread bedbugs to other people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46118789\">",
"      <span class=\"h1\">",
"       Can bedbug bites be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The only way to prevent bites is by getting rid of the bedbugs. Also, do not sleep or stay over in a place that you know has bedbugs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H46118894\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/30/14817?source=see_link\">",
"       Patient information: Bedbugs (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/13/36049?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15346 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36049=[""].join("\n");
var outline_f35_13_36049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46118747\">",
"      What are bedbugs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46118754\">",
"      What do bedbug bites look like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46118761\">",
"      Is there a test to tell if I have bedbug bites?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46118768\">",
"      Is there anything I can do on my own to help my bites feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46118775\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46118782\">",
"      What should I do about the bedbugs in my home?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46118789\">",
"      Can bedbug bites be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46118894\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/1/20500\">",
"      Bedbugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/30/14817?source=related_link\">",
"      Patient information: Bedbugs (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_13_36050="Insertion site infection in HIV";
var content_f35_13_36050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insertion site infection due to staphylococcus aureus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breakdown of the skin with pus at the insertion site of a one-month old central venous catheter in an HIV-infected patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams &amp; Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36050=[""].join("\n");
var outline_f35_13_36050=null;
var title_f35_13_36051="Kanamycin: Patient drug information";
var content_f35_13_36051=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Kanamycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"     see \"Kanamycin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause kidney function to get worse and hearing loss, and it may change your sense of balance. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to kanamycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hearing loss, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Some side effects may happen up to 2 weeks after the shot. Report them to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11383 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36051=[""].join("\n");
var outline_f35_13_36051=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015527\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015529\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015528\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015533\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015534\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015536\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015531\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015537\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015538\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=related_link\">",
"      Kanamycin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_13_36052="Vitamin D2 (ergocalciferol): Patient drug information";
var content_f35_13_36052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin D2 (ergocalciferol): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/45/7895?source=see_link\">",
"     see \"Vitamin D2 (ergocalciferol): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/10/27814?source=see_link\">",
"     see \"Vitamin D2 (ergocalciferol): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calciferol&trade; [OTC];",
"     </li>",
"     <li>",
"      Drisdol&reg;;",
"     </li>",
"     <li>",
"      Drisdol&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Drisdol&reg;;",
"     </li>",
"     <li>",
"      Ostoforte&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12676142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to aid diet needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat poor parathyroid function.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691518",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692046",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat rickets.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ergocalciferol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels, high vitamin D levels, or malabsorption syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of vitamin D.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take cholestyramine, mineral oil, antacids that have magnesium, or orlistat with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High calcium level. Signs include weakness, confusion, feeling tired, headache, upset stomach and throwing up, hard stools (constipation), or bone pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given. Use a dropper to measure this liquid drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12426 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36052=[""].join("\n");
var outline_f35_13_36052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166127\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166128\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12676142\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019051\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019050\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019055\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019056\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019058\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019053\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019054\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019059\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019060\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/45/7895?source=related_link\">",
"      Vitamin D2 (ergocalciferol): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/10/27814?source=related_link\">",
"      Vitamin D2 (ergocalciferol): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_13_36053="Pigmented melanocytic lesions II";
var content_f35_13_36053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Dermoscopic structures seen in melanocytic lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Aggregated globules (solid square) and pigment network (solid arrow) in a melanocytic nevus.",
"    <br>",
"     (B) Homogeneous blue pigmentation seen in a blue nevus.",
"     <br>",
"      (C, D) Streaks: Pseudopods in a Spitz nevus (C) and radial streaming in a melanoma (D).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36053=[""].join("\n");
var outline_f35_13_36053=null;
var title_f35_13_36054="Bronchocentric granuloma High";
var content_f35_13_36054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchocentric granulomatosis in a patient with ABPA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Higher magnification photomicrograph (original magnification 200x) from&nbsp;a specimen showing transition from respiratory epithelium to granulomatous inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36054=[""].join("\n");
var outline_f35_13_36054=null;
var title_f35_13_36055="Main pancreatic duct stricture";
var content_f35_13_36055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62772%7EGAST%2F63364%7EGAST%2F59903%7EGAST%2F70294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62772%7EGAST%2F63364%7EGAST%2F59903%7EGAST%2F70294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic duct stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pancreatogram shows a dominant stricture (arrow) in the head of the pancreas following pancreatic duct stenting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic parenchymal changes following pancreatic stent placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound shows hypoechoic parenchymal changes (P) surrounding the proximal end of a stricture following pancreatic duct stenting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balloon dilation of pancreatic duct stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image shows a balloon that has been inflated within a stricture in the main pancreatic duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Residual pancreatic duct stricture following balloon dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follow-up pancreatogram after balloon dilation of a pancreatic duct stricture shows an asymptomatic short stricture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Catalano, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36055=[""].join("\n");
var outline_f35_13_36055=null;
var title_f35_13_36056="Erlotinib: Drug information";
var content_f35_13_36056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erlotinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/57/41877?source=see_link\">",
"    see \"Erlotinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tarceva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3011589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tarceva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Epidermal Growth Factor Receptor (EGFR) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Nonsmall cell lung cancer (NSCLC), refractory:",
"     </b>",
"     Oral: 150 mg once daily until disease progression or unacceptable toxicity (Shepherd, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      NSCLC, maintenance therapy:",
"     </b>",
"     Oral: 150 mg once daily until disease progression or unacceptable toxicity (Capuzzo, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pancreatic cancer:",
"     </b>",
"     Oral: 100 mg once daily until disease progression or unacceptable toxicity (in combination with gemcitabine) (Moore, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      NSCLC, first-line therapy in patients with EGFR mutations (U.S. unlabeled use):",
"     </b>",
"     Oral: 150 mg once daily until disease progression or unacceptable toxicity (Rosell, 2012; Zhou, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      CYP3A4 inhibitors:",
"     </i>",
"     Consider dose reductions for severe adverse reactions when erlotinib is administered concomitantly with strong CYP3A4 inhibitors (eg, azole antifungals, clarithromycin, erythromycin, nefazodone, protease inhibitors, telithromycin). Dose reduction (if required) should be done in decrements of 50 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Concomitant CYP3A4 and CYP1A2 inhibitor (eg, ciprofloxacin):",
"     </i>",
"     Consider dose reductions if severe adverse reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      CYP3A4 inducers:",
"     </i>",
"     Alternatives to the enzyme-inducing agent should be utilized first. Concomitant administration with CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifamycins, and St John&rsquo;s wort) may require erlotinib increased doses (increase as tolerated at 2-week intervals); doses &gt;150 mg/day should be considered with rifampin (the maximum erlotinib dose studied in combination with rifampin was 450 mg). Immediately reduce erlotinib dose to recommended starting dose when CYP3A4 inducer is discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment for concomitant smoking:",
"     </b>",
"     A dose increase to a maximum dose of 300 mg (with careful monitoring) may be required in patients who continue to smoke; immediately reduce erlotinib dose to recommended starting dose upon smoking cessation.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F1990182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied), although &lt;9% of a single dose is excreted in the urine. Interrupt treatment (or discontinue) for risk of renal failure due to dehydration; may resume after euvolemia re-established.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F166471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients with normal hepatic function at baseline: Total bilirubin &gt;3 times ULN and/or transaminases &gt;5 times ULN: Interrupt or discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients with baseline hepatic impairment: Total bilirubin &gt;3 times ULN: Use extreme caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; however, a reduced dose should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (including total bilirubin &gt;3 times ULN and/or transaminases &gt;5 times ULN): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      The following adjustments have also been studied:",
"     </i>",
"     A reduced starting dose (75 mg once daily) has been recommended in patients with hepatic dysfunction (AST &ge;3 times ULN or direct bilirubin 1-7 mg/dL), with individualized dosage escalation if tolerated (Miller, 2007); another study determined that pharmacokinetic and safety profiles were similar between patients with normal hepatic function and moderate hepatic impairment (O&rsquo;Bryant, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F166487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dose reductions should be made in 50 mg decrements.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Bullous, blistering or exfoliative skin toxicity, acute or worsening ocular toxicities, or dehydration with risk for renal failure:",
"     </i>",
"     Interrupt or discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Diarrhea:",
"     </i>",
"     Manage with loperamide; in severe diarrhea (unresponsive to loperamide) or dehydration due to diarrhea, reduce dose or temporarily interrupt treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Gastrointestinal perforation, hepatic failure:",
"     </i>",
"     Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Hepatotoxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Worsening liver function (not yet severe): Consider treatment interruption or dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Significant changes in liver function (eg, doubling of total bilirubin and/or tripling of transaminases from baseline): Interrupt or discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Pulmonary symptoms:",
"     </i>",
"     Acute onset (or worsening) of pulmonary symptoms (eg, dyspnea, cough, fever): Interrupt treatment and evaluate for drug-induced interstitial lung disease; discontinue permanently with development of interstitial lung disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Severe skin reaction:",
"     </i>",
"     Reduce dose or temporarily interrupt treatment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tarceva&reg;: 25 mg, 100 mg, 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F166447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends administration on an empty stomach (at least 1 hour before or 2 hours after the ingestion of food).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     For patients unable to swallow whole, tablets may be dissolved in 100 mL water and administered orally or via feeding tube (silicone-based); to ensure full dose is received, rinse container with 40 mL water, administer residue and repeat rinse (data on file, Genentech; Siu, 2007; Soulieres, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) refractory to at least 1 prior chemotherapy regimen (as monotherapy); maintenance treatment of locally advanced or metastatic NCSLC which has not progressed after 4-6 cycles of first line platinum-based chemotherapy; locally  advanced, unresectable or metastatic pancreatic cancer (first-line therapy in combination with gemcitabine)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: First-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) with known EGFR mutation (as monotherapy); treatment of locally advanced or metastatic NSCLC refractory to at least 1 prior chemotherapy regimen and positive or unknown EGFR status (as monotherapy); maintenance treatment of locally advanced or metastatic NCSLC which has not progressed after 4 cycles of first line platinum-based chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7789163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     First-line treatment of NSCLC with known EGFR mutation (unlabeled in U.S.)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2138083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Erlotinib may be confused with crizotinib, eribulin, gefitinib, imatinib, regorafenib, SUNItinib, vandetanib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Adverse reactions reported with monotherapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain (&le;17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Fatigue (9% to 52%), pyrexia (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash (49% to 75%; grade 3: 5% to 13%; grade 4: &lt;1%; median onset: 8 days), dry skin (4% to 17%), paronychia (4% to 16%), alopecia (14% to 15%), pruritus (7% to 13%), acne (6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (20% to 57%; grade 3: 2% to 6%; grade 4: &lt;1%; median onset: 12 days), anorexia (9% to 52%), nausea (23% to 33%), appetite decreased (&le;28%), vomiting (13% to 23%), stomatitis (11% to 17%), mucosal inflammation (&le;17%), abdominal pain (3% to 11%), constipation (&le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia (&le;11%; grade 4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (&le;53%), back pain (&le;16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ocular: Conjunctivitis (12%), keratoconjunctivitis sicca (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Dyspnea (41%), cough (33% to 45%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection (4% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Pain (&le;9%), headache (&le;7%), anxiety (&le;5%), dizziness (&le;4%), dysphonia (&le;4%), insomnia (&le;4%), neurotoxicity (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Folliculitis (&le;8%), nail disorder (&le;7%), exfoliative rash (5%), hypertrichosis (5%), skin fissures (5%), dermatitis acneiform (4% to 5%), erythema (&le;5%), dermatitis (4%), erythematous rash (&le;4%), palmar-plantar erythrodysesthesia (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (&le;5%), weight loss (4% to 5%), xerostomia (&le;3%), taste disturbance (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Lymphopenia (&le;4%; grade 3: 1%), leukopenia (&le;3%), thrombocytopenia (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (7%; grade 3: &le;1%), ALT increased (grade 2: 2% to 4%; grade 3: 1% to 3%), GGT increased (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (&le;10%), musculoskeletal pain (&le;9%), bone pain (&le;4%), muscle spasms (&le;4%), musculoskeletal chest pain (&le;4%), paresthesia (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Otic: Tinnitus (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Renal failure (&le;1%), serum creatinine increased (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (&le;7%), epistaxis (&le;4%), pulmonary embolus (&le;4%), respiratory tract infection (&le;4%), pneumonitis/pulmonary infiltrate (3%), pulmonary fibrosis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%: Interstitial lung disease-like events",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adverse reactions reported with combination (erlotinib plus gemcitabine) therapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (37%), thrombotic events (grades 3/4: 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (73% to 79%), fever (36%), depression (19%), dizziness (15%), headache (15%), anxiety (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (69%), alopecia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (60%), anorexia (52%), diarrhea (48%), abdominal pain (46%), vomiting (42%), weight loss (39%), stomatitis (22%), dyspepsia (17%), flatulence (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (grade 2: 31%, grade 3: 13%, grade 4: &lt;1%), AST increased (grade 2: 24%, grade 3: 10%, grade 4 &lt;1%), hyperbilirubinemia (grade 2: 17%, grade 3: 10%, grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (25%), myalgia (21%), neuropathy (13%), rigors (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (24%), cough (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (39%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (&lt;5%), syncope (&lt;5%), deep venous thrombosis (4%), cerebrovascular accident (2%; including cerebral hemorrhage), MI/myocardial ischemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Ileus (&lt;5%), pancreatitis (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia (&lt;5%), microangiopathic hemolytic anemia with thrombocytopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal insufficiency (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Interstitial lung disease-like events (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Mono- or combination therapy:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, blistering/bullous/exfoliative skin conditions (suggesting Stevens-Johnson syndrome or TEN), bronchiolitis, corneal perforation, corneal ulcerations, episcleritis, eye lash disorders (ingrown lashes, excessive growth, thickening), gastritis, gastroduodenal ulcers, GI bleeding, GI hemorrhage, GI perforation, hearing loss, hematemesis, hematochezia, hepatic failure, hepatorenal syndrome, hepatotoxicity, hirsutism, hyperpigmentation, hypokalemia, keratitis, melena, peptic ulcer bleeding, photosensitivity, rash (acneiform; sparing prior radiation field), skin fissures, tympanic membrane perforation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to erlotinib or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: Cerebrovascular accidents, MI, and myocardial ischemia have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity: Bullous, blistering, or exfoliating skin conditions, some suggestive of Stevens-Johnson or toxic epidermal necrolysis (TEN) have been reported (some fatal). An acne-like rash commonly appears on the face, back, and upper chest. Generalized  or severe acneiform, erythematous or maculopapular rash may occur. Skin rash may correlate with treatment response and prolonged survival (Saif, 2008); management of skin rashes that are not serious should include alcohol-free lotions, topical antibiotics, or topical corticosteroids, or if necessary, oral antibiotics and systemic corticosteroids; avoid sunlight. Reduce dose or temporarily interrupt treatment for severe skin reactions; interrupt or discontinue treatment for bullous, blistering, or exfoliative skin toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal (GI) perforation: GI perforation (including fatalities) has been reported with use; risk for perforation is increased with concurrent anti-angiogenic agents, corticosteroids, NSAIDs, and/or taxane based-therapy, and patients with history of peptic ulcers or diverticular disease. Permanently discontinue in patients who develop perforation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia has been reported (rarely) with erlotinib in combination with gemcitabine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Liver enzyme elevations have been reported. Hepatic failure and hepatorenal syndrome have also been reported (some fatal), particularly in patients with baseline hepatic impairment. Monitor liver function; patients with any hepatic impairment (total bilirubin &gt;ULN; Child-Pugh class A, B, or C) should be closely monitored, including those with hepatic disease due to tumor burden. Use with extreme caution in patients with total bilirubin &gt;3 times ULN. Dosage reduction, interruption or discontinuation may be recommended for changes in hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular toxicity: Corneal perforation and ulceration have been reported with use; abnormal eyelash growth, keratoconjunctivitis sicca, or keratitis have also been reported and are known risk factors for corneal ulceration/perforation. Interrupt or discontinue treatment in patients presenting with eye pain or other acute or worsening ocular symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Rare, sometimes fatal, interstitial lung disease (ILD) has occurred; symptoms include acute respiratory distress syndrome, interstitial pneumonia, obliterative bronchiolitis, pneumonitis (including radiation and hypersensitivity), pulmonary fibrosis, and pulmonary infiltrates. The onset of symptoms has been within 5 days to more than 9 months after treatment initiation (median: 39 days). Interrupt treatment for unexplained new or worsening pulmonary symptoms (dyspnea, cough, and fever); discontinue for confirmed ILD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Acute renal failure (some fatal), renal insufficiency, and hepatorenal syndrome have been reported, either secondary to hepatic impairment at baseline or due to severe dehydration; use with caution in patients with or at risk for renal impairment. Monitor closely for dehydration; monitor renal function and electrolytes in patients at risk for dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NSCLC genomics: EGFR mutations, specifically exon 19 deletions and exon 21 mutation (L858R), are associated with better response to erlotinib in patients with NSCLC (Riely, 2006). Erlotinib treatment is not recommended in patients with NSCLC with",
"     <i>",
"      K-ras",
"     </i>",
"     mutations; they are not likely to benefit from erlotinib treatment (Eberhard, 2005; Miller, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: Elevated INR and bleeding events have been reported; monitor for INR changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gemcitabine: MI, CVA, and microangiopathic hemolytic anemia with thrombocytopenia have been noted in patients receiving concomitant erlotinib and gemcitabine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concurrent use with CYP3A4 inhibitors and moderate or strong CYP3A4 inducers may affect erlotinib levels. Consider alternative agents to CYP3A4 inducers to avoid the potential for CYP-mediated interactions; use with caution in patients taking strong CYP3A4 inhibitors. Consider erlotinib dosage modification if concurrent use with CYP3A4 inhibitors/inducers cannot be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Platinum-based therapy: Concurrent erlotinib plus platinum-based chemotherapy is not recommended for first-line treatment of locally advanced or metastatic NSCLC due to a lack of clinical benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: Erlotinib levels may be lower in patients who smoke; advise patients to stop smoking. Smokers treated with 300 mg/day exhibited steady-state erlotinib levels comparable to former- and never-smokers receiving 150 mg/day (Hughes, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose intolerance: Product may contain lactose; avoid use in patients with Lapp lactase deficiency, glucose-galactose malabsorption, or glucose intolerance.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Erlotinib. Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May increase the serum concentration of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May increase the serum concentration of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Erlotinib. Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Erlotinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F166463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Erlotinib bioavailability is increased with food. Grapefruit or grapefruit juice may decrease metabolism and increase erlotinib plasma concentrations. Management: Take on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Avoid grapefruit and grapefruit juice. Maintain adequate nutrition and hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may increase metabolism and decrease erlotinib concentrations. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated fetal harm and abortion. Women of childbearing potential should be advised to avoid pregnancy; adequate contraception is recommended during treatment and for at least 2 weeks after treatment has been completed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14383338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue breast-feeding or discontinue erlotinib should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5028520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take this medicine an empty stomach, 1 hour before or 2 hours after a meal. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F166452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tarceva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $2221.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $6102.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (30): $6902.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F166442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests (transaminases, bilirubin, and alkaline phosphatase); monitor more frequently with worsening liver function; periodic renal function tests and serum electrolytes (in patients at risk for dehydration); hydration status; EGFR mutation status in patients with NSCLC adenocarcinoma (Keedy, 2011)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tarceva (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The mechanism of erlotinib's antitumor action is not fully characterized. It is known to inhibit overall epidermal growth factor receptor (HER1/EGFR) - tyrosine kinase. Active competitive inhibition of adenosine triphosphate inhibits downstream signal transduction of ligand dependent HER1/EGFR activation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 60% on an empty stomach; almost 100% on a full stomach",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 94-232 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 92% to 95% to albumin and &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP3A4 (major), CYP1A1 (minor), CYP1A2 (minor), and CYP1C (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Almost 100% when given with food; 60% without food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily as metabolites: Feces (83%; 1% as unchanged drug); urine (8%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Azzoli CG, Baker S Jr, Temin S, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(36):6251-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/19917871/pubmed\" id=\"19917871\" target=\"_blank\">",
"        19917871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blank SV, Chang R, and Muggia F, &ldquo;Epidermal Growth Factor Receptor Inhibitors for the Treatment of Epithelial Ovarian Cancer,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 2005, 19(4):553-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/15934521/pubmed\" id=\"15934521\" target=\"_blank\">",
"        15934521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeck S, Vehling-Kaiser U, Waldschmidt D, et al, &ldquo;Erlotinib 150 mg Daily Plus Chemotherapy in Advanced Pancreatic Cancer: An Interim Safety Analysis of a Multicenter, Randomized, Cross-Over Phase III Trial of the 'Arbeitsgemeinschaft Internistische Onkologie',&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2010, 21(1):94-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/19770635/pubmed\" id=\"19770635\" target=\"_blank\">",
"        19770635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonomi P, &ldquo;Erlotinib: A New Therapeutic Approach for Non-Small Cell Lung Cancer,&rdquo; Expert Opin Investig Drugs, 2003, 12(8):1395-1401.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/12882624/pubmed\" id=\"12882624\" target=\"_blank\">",
"        12882624",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bulgaru AM, Mani S, Goel S, et al, &ldquo;Erlotinib (Tarceva): A Promising Drug Targeting Epidermal Growth Factor Receptor Tyrosine Kinase,&rdquo;",
"      <i>",
"       Expert Rev Anticancer Ther",
"      </i>",
"      , 2003, 3(3):269-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/12820772/pubmed\" id=\"12820772\" target=\"_blank\">",
"        12820772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cappuzzo F, Ciuleanu T, Stelmakh L, et al, &ldquo;Erlotinib as Maintenance Treatment in Advanced Non-Small-cell Lung Cancer: A Multicentre, Randomised, Placebo-Controlled Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(6):521-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/20493771/pubmed\" id=\"20493771\" target=\"_blank\">",
"        20493771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cataldo VD, Gibbons DL, P&eacute;rez-Soler R, et al, &ldquo;Treatment of Non-Small-Cell Lung Cancer With Erlotinib or Gefitinib,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(10):947-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/21388312/pubmed\" id=\"21388312\" target=\"_blank\">",
"        21388312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ciuleanu T, Stelmakh L, Cicenas S, et al, &ldquo;Efficacy and Safety of Erlotinib Versus Chemotherapy in Second-Line Treatment of Patients With Advanced, Non-Small-Cell Lung Cancer With Poor Prognosis (TITAN): A Randomised Multicentre, Open-Label, Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(3):300-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/22277837/pubmed\" id=\"22277837\" target=\"_blank\">",
"        22277837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooley ME, Emmons KM, Li, H, et al, &ldquo;Smoking History, Drug Toxicity, and Survival in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFI-TKI) Drugs,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15 Supp):9570 [abstract 9570 from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coudert B, Ciuleanu T, Park K, et al, &ldquo;Survival Benefit With Erlotinib Maintenance Therapy in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) According to Response to First-Line Chemotherapy,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(2):388-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/21610154/pubmed\" id=\"21610154\" target=\"_blank\">",
"        21610154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eberhard DA, Johnson BE, Amler LC, et al, &ldquo;Mutations in the Epidermal Growth Factor Receptor and in KRAS are Predictive and Prognostic Indicators in Patients With Non-Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(25):5900-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/16043828/pubmed\" id=\"16043828\" target=\"_blank\">",
"        16043828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herchenhorn D, Dias FL, Viegas CM, et al, &ldquo;Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck,&rdquo;",
"      <i>",
"       Int J Radiat Oncol Biol Phys",
"      </i>",
"      , 2010, 78(3):696-702.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/20421154/pubmed\" id=\"20421154\" target=\"_blank\">",
"        20421154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herbst RS, Prager D, Hermann R, et al, &ldquo;TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(25):5892-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/16043829/pubmed\" id=\"16043829\" target=\"_blank\">",
"        16043829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hidalgo M and Bloedow D, &ldquo;Pharmacokinetics and Pharmacodynamics: Maximizing the Clinical Potential of Erlotinib (Tarceva),&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2003, 30(3 Suppl 7):25-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/12840798/pubmed\" id=\"12840798\" target=\"_blank\">",
"        12840798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes AN, O&rsquo;Brien ME, Petty WJ, et al, &ldquo;Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(8):1220-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/19164205/pubmed\" id=\"19164205\" target=\"_blank\">",
"        19164205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jackman DM, Sequist LV, Cioffrei L, et al, &rdquo;Impact of EGFR and KRAS Genotype on Outcome in a Clinical Trial Registry of NSCLC Patients Initially Treated With Erlotinib or Gefitinib,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      ,  2008, 26(15 Supp) [abstract 8035  from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keedy VL, Temin S, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15):2121-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/21482992/pubmed\" id=\"21482992\" target=\"_blank\">",
"        21482992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee SM, Buchler T, Joseph T, et al, &ldquo;Bilateral Eardrum Perforation After Long-Term Treatment With Erlotinib,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15):2582-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/18487575/pubmed\" id=\"18487575\" target=\"_blank\">",
"        18487575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee S, Rudd R, Khan I, et al, &ldquo;TOPICAL: Randomized Phase III Trial of Erlotinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and Unsuitable for First-Line Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 18(15s):7504 [abstract 7504 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massarelli E, Varella-Garcia M, Tang X, et al, &ldquo;KRAS Mutation is an Important Predictor of Resistance to Therapy With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2007, 13(10):2890-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/17504988/pubmed\" id=\"17504988\" target=\"_blank\">",
"        17504988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller AA, Murry DJ, Owzar K, et al, &ldquo;Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(21):3055-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/17634483/pubmed\" id=\"17634483\" target=\"_blank\">",
"        17634483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller VA, Riely GJ, Zakowski MF, et al, &ldquo;Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(9):1472-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/18349398/pubmed\" id=\"18349398\" target=\"_blank\">",
"        18349398",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mir O, Blanchet B, and Goldwasser F, &ldquo;Drug-Induced Effects on Erlotinib Metabolism,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(4):379-80.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mita SS and Simcock R, &ldquo;Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy Field,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(16):e27-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore MJ, Goldstein D, Hamm J, et al, &ldquo;Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(15):1960-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/17452677/pubmed\" id=\"17452677\" target=\"_blank\">",
"        17452677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Bryant CL, Haluska P, Rosen L, et al, &ldquo;An Open-Label Study to Describe Pharmacokinetic Parameters of Erlotinib in Patients With Advanced Solid Tumors With Adequate and Moderately Impaired Hepatic Function,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2012, 69(3):605-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/21938545/pubmed\" id=\"21938545\" target=\"_blank\">",
"        21938545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez-Soler R, Chachoua A, Hammond LA, et al, &ldquo;Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(16):3238-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/15310767/pubmed\" id=\"15310767\" target=\"_blank\">",
"        15310767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riely GJ, Pao W, Pham D, et al, &ldquo;Clinical Course of Patients With Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated With Gefitinib or Erlotinib,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2006, 12(3 Pt 1):839-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/16467097/pubmed\" id=\"16467097\" target=\"_blank\">",
"        16467097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosell R, Carcereny E, Gervais R, et al, &ldquo;Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(3):239-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/22285168/pubmed\" id=\"22285168\" target=\"_blank\">",
"        22285168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosell R, Moran T, Queralt C, et al, &ldquo;Screening for Epidermal Growth Factor Mutations in Lung Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(10):958-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/19692684/pubmed\" id=\"19692684\" target=\"_blank\">",
"        19692684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saif MS, Merikas I, Tsimboukis S, et al, &ldquo;Erlotinib-Induced Skin Rash. Pathogenesis, Clinical Significance and Management in Pancreatic Cancer Patients,&rdquo;",
"      <i>",
"       JOP",
"      </i>",
"      , 2008, 9(3):267-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/18469438/pubmed\" id=\"18469438\" target=\"_blank\">",
"        18469438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shahrokni A, Matuszczak J, Rajebi MR, et al, &ldquo;Erlotinib-Induced Episcleritis in a Patient With Pancreatic Cancer,&rdquo;",
"      <i>",
"       JOP",
"      </i>",
"      , 2008, 9(2):216-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/18326933/pubmed\" id=\"18326933\" target=\"_blank\">",
"        18326933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al, &ldquo;Erlotinib in Previously Treated Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(2):123-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/16014882/pubmed\" id=\"16014882\" target=\"_blank\">",
"        16014882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siu LL, Soulieres D, Chen EX, et al, &ldquo;Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(16):2178-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/17538162/pubmed\" id=\"17538162\" target=\"_blank\">",
"        17538162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soulieres D, Senzer NN, Vokes EE, et al, &ldquo;Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(1):77-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/14701768/pubmed\" id=\"14701768\" target=\"_blank\">",
"        14701768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spigel DR, Lin M, O'Neill V, et al, &ldquo;Final Survival and Safety Results From a Multicenter, Open-Label, Phase 3b Trial of Erlotinib in Patients With Advanced Nonsmall Cell Lung Cancer,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 112(12):2749-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/18438878/pubmed\" id=\"18438878\" target=\"_blank\">",
"        18438878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Vervenne WL, Bennouna J, et al, &ldquo;Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(13):2231-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/19307500/pubmed\" id=\"19307500\" target=\"_blank\">",
"        19307500",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wacker B, Nagrani T, Weinberg J, et al, &ldquo;Correlation Between Development of Rash and Efficacy in Patients Treated With the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2007, 13(13):3913-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/17606725/pubmed\" id=\"17606725\" target=\"_blank\">",
"        17606725",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheatley-Price P, Ding K, Seymour L, et al, &ldquo;Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: an Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(14):2350-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Willett CG, Czito BG, Bendell JC, et al, &ldquo;Locally Advanced Pancreatic Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(20):4538-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/16002845/pubmed\" id=\"16002845\" target=\"_blank\">",
"        16002845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhou C, Wu YL, Chen G, et al, &ldquo;Erlotinib Versus Chemotherapy as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011,12(8):735-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/13/36056/abstract-text/21783417 /pubmed\" id=\"21783417 \" target=\"_blank\">",
"        21783417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8736 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36056=[""].join("\n");
var outline_f35_13_36056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166466\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011589\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166486\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166469\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166470\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1990182\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166471\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166487\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166444\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166432\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166447\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166446\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7789163\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2138083\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166484\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166450\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166434\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166479\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166438\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166463\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166440\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166453\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166475\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14383338\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5028520\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166452\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166442\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869379\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166433\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166449\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8736\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8736|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/57/41877?source=related_link\">",
"      Erlotinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_13_36057="Primary lung graft dysfunction";
var content_f35_13_36057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary lung graft dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/13/36057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36057/contributors\">",
"     Marcelo Cypel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36057/contributors\">",
"     Tom Waddell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36057/contributors\">",
"     Shaf Keshavjee, MD, MSc, FRCSC, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/13/36057/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36057/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/13/36057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36057/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/13/36057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary graft dysfunction (PGD) after lung transplantation represents a multifactorial injury to the transplanted lung that develops in the first 72 hours after transplantation; it is variously referred to as \"ischemia-reperfusion injury\", \"early graft dysfunction\", and \"reimplantation edema.\" PGD is characterized by severe hypoxemia, lung edema, and the radiographic appearance of diffuse pulmonary opacities without other identifiable cause. The typical pathologic pattern of PGD is diffuse alveolar damage.",
"   </p>",
"   <p>",
"    Despite significant advances in organ preservation, surgical technique, and perioperative care, PGD is responsible for significant morbidity and mortality after lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology, risk factors, diagnosis, grading, and strategies to prevent PGD are reviewed here. Postoperative management following lung transplantation, evaluation of acute lung transplant rejection, and immunosuppression following lung transplantation are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3994?source=see_link\">",
"     \"Evaluation and treatment of acute lung transplant rejection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3688?source=see_link\">",
"     \"Induction immunosuppression following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of PGD is reported to be in the range of 10 to 25 percent; it is the leading cause of early death after lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Survivors of PGD tend to have a longer duration of mechanical ventilation, longer hospital stay, and lower lung function over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, a retrospective study of 255 lung transplant procedures found that recipients with severe PGD (",
"    <a class=\"graphic graphic_table graphicRef78107 \" href=\"mobipreview.htm?18/6/18539\">",
"     table 1",
"    </a>",
"    ) versus those without had a 30 day mortality of 63 versus 9 percent and duration of mechanical ventilation of 15 versus 1 day(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PGD reflects the summation of injury inflicted on the donor lung by the transplant process (retrieval, preservation, implantation, and reperfusion) and by other factors such as acid aspiration, pneumonia, and microtrauma from mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/7\">",
"     7",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef57115 \" href=\"mobipreview.htm?3/61/4063\">",
"     figure 1",
"    </a>",
"    ). Recipient factors also play a role in the development of PGD. For example, recipients with pulmonary fibrosis and primary pulmonary hypertension have higher incidence of PGD compared with patients with emphysema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pretransplant factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors related to the donor may contribute to the development of PGD. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain death is associated with altered homeostatic regulation, disturbed endocrine function (eg, diabetes insipidus), and inflammatory cytokine release [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/8\">",
"       8",
"      </a>",
"      ]. These factors, cytokine release in particular, can be associated with marked detrimental effects. For example, the level of IL-8 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/9\">",
"       9",
"      </a>",
"      ] and the ratio of IL-6 (pro-inflammatory) to IL-10 (anti-inflammatory) correlate with development of PGD and 30 day mortality, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12425?source=see_link\">",
"       \"Lung transplantation: Deceased donor evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Donor hypotension before organ procurement was associated with acute severe lung injury in an animal model [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/11\">",
"       11",
"      </a>",
"      ]. A similar result has been noted in kidney and liver transplantation. Upregulation of inflammatory mediators is thought to mediate organ injury during hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Correction of neurogenic hypotension (eg, with arginine vasopressin or norepinephrine) limits lung edema, reduces pulmonary capillary leak, and modulates systemic and pulmonary inflammatory responses to brain death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ventilator-associated lung injury due to alveolar over distension may also play a role, as all donors are mechanically ventilated prior to lung retrieval. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16182?source=see_link\">",
"       \"Ventilator-associated lung injury\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these clinical features may enhance",
"    <span class=\"nowrap\">",
"     proinflammatory/ischemic",
"    </span>",
"    sequelae in the donor lung, leading to a higher chance of PGD in the recipient. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Retrieval/cold storage",
"    </span>",
"    &nbsp;&mdash;&nbsp;To preserve the integrity of the donor organ after retrieval, all deceased donor organs are stored at below normal body temperature. A number of deleterious events may occur during the cold ischemic phase, particularly if the duration of cold storage time is prolonged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothermic preservation leads to the following biochemical and histological abnormalities in a time dependent manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/7,17,18\">",
"     7,17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased oxidative stress",
"     </li>",
"     <li>",
"      Sodium pump inactivation with accumulation of intracellular sodium and loss of intracellular potassium",
"     </li>",
"     <li>",
"      Intracellular calcium overload (which may be limited by treatment of the donor with a calcium channel blocker prior to organ retrieval)",
"     </li>",
"     <li>",
"      Iron release",
"     </li>",
"     <li>",
"      Cell death via apoptosis and necrosis",
"     </li>",
"     <li>",
"      Release of pro-and anti-inflammatory cytokines, such as TNF-a, IFN-g, IL-8, IL-10, IL-12 and IL-18.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative importance of each of these abnormalities in contributing to lung dysfunction post-transplantation is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ischemia/reperfusion injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal and human studies have been performed to characterize the molecular and cellular consequences of",
"    <span class=\"nowrap\">",
"     ischemia/reperfusion",
"    </span>",
"    injury in lung transplantation. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upregulation of adhesion molecules &ndash; Leukocyte recruitment by the increased expression of adhesion molecules may contribute to acute lung injury following lung transplantation. Evidence for upregulation of adhesion molecules comes from a prospective study of 128 lung transplant recipients in which higher plasma levels of intercellular adhesion molecule 1 (ICAM1) were associated with PGD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prothrombotic state &ndash; Hypoxia during ischemia induces endothelial cells to develop procoagulant properties, including up-regulation of tissue factor and plasminogen inhibitor-1 (PAI-1), which contribute to microvascular thrombosis and impede microcirculatory blood flow after reperfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Release of proinflammatory mediators &ndash; Ischemia-reperfusion injury induces the release of pro-inflammatory cytokines, including the chemokine IL-8, which significantly increases after reperfusion and correlates negatively with graft function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Release of markers of alveolar epithelial injury &ndash; Plasma levels of the soluble receptor for advanced glycation end products (sRAGE) are elevated at 6 and 24 hours after lung transplantation in patients who subsequently develop PGD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/21\">",
"       21",
"      </a>",
"      ]. In animal models and human cases of acute lung injury, sRAGE levels appear to correlate with injury to alveolar type I cells; however, their role in PGD is not fully characterized.",
"     </li>",
"     <li>",
"      Lipid mediated cellular injury &ndash; Activation of phospholipase A2 induces the production of platelet-activating factor, which is a potent mediator of inflammation and is important in the mobilization of arachidonic acid.",
"     </li>",
"     <li>",
"      Complement activation &ndash; The complement pathway plays an important role in the injury related to ischemia and reperfusion. Products of complement activation cause smooth muscle contraction and increased vascular permeability. Moreover, the activated complement fragment C5a amplifies the inflammatory response via its chemoattractant properties [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endothelin activation &ndash; In addition to being a potent vasoconstrictor, endothelin-1 can stimulate the production of cytokines by monocytes and macrophages; it also promotes the retention of neutrophils in the lung [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukocyte activation &ndash; Ischemia-reperfusion injury occurs in a biphasic pattern. Donor macrophages are activated during ischemia and mediate part of the early phase of reperfusion injury, whereas recipient neutrophils and lymphocytes are primarily involved in the delayed phase of reperfusion injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/24-27\">",
"       24-27",
"      </a>",
"      ]. CD4+ T lymphocytes accumulate in lung tissue after reperfusion and contribute to the delayed phase of reperfusion injury by releasing interferon-gamma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Post-transplant factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors post-transplantation may be involved in the development of PGD. These include aspiration, fluid overload, hypotension, mechanical ventilation (particularly the use of high tidal volumes), and pneumonia.",
"   </p>",
"   <p>",
"    These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the causes of lung injury pertaining to organ procurement, storage, and reperfusion that are detailed above, certain donor and recipient risk factors for PGD have been identified in retrospective reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Donor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor characteristics, such as age, female gender, African-American race, and smoking history are associated with an increased risk of PGD; however, the specific characteristics identified vary somewhat among studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 402 lung transplant recipients with severe PGD, multivariate analysis identified donor age and smoking history as risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another review of 255 lung transplant procedures found that female gender, African-American donor, and donor age (over 45 or under 21) were associated with increased risk of PGD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Donor fat embolism and thromboembolism have also been associated with an increased risk of severe PGD. In one study of 135 recipients, there was a 21- and 5-fold increased risk of developing PGD among those who received lungs with fat emboli and thromboemboli, respectively, compared with patients who obtained lungs without these abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recipient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying lung disease that led to the need for lung transplant may influence the risk of PGD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A recipient diagnosis of pulmonary arterial hypertension (PAH), increases the risk of PGD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/2,29,31\">",
"       2,29,31",
"      </a>",
"      ]. Patients with pulmonary fibrosis with elevated pulmonary artery pressures before transplant also have an increased risk of PGD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, COPD had the lowest risk and pulmonary fibrosis was intermediate between COPD and idiopathic pulmonary arterial hypertension (IPAH, formerly called primary pulmonary hypertension) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association between recipient lung disease and risk of PGD is confounded by the variable use of cardiopulmonary bypass during transplantation based upon the underlying lung disease (ie, patients with IPAH almost always undergo cardiopulmonary bypass at the time of transplant). However, increasing evidence suggests that cardiopulmonary bypass plays a minor role in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal clinical manifestations of PGD are declining oxygenation and diffuse pulmonary opacities in the transplanted lung(s) that develop in the first 72 hours following transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/7\">",
"     7",
"    </a>",
"    ]. Additional clinical findings may include decreased pulmonary compliance, increased pulmonary vascular resistance, and intrapulmonary shunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Grading system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of PGD is graded based on the ratio of arterial oxygen pressure to inspired oxygen concentration",
"    <span class=\"nowrap\">",
"     (PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"     ).",
"    </span>",
"    The International Society of Heart Lung Transplantation has proposed the following grading system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0 -",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &gt;300 and normal chest radiograph",
"     </li>",
"     <li>",
"      Grade 1 -",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &gt;300 and diffuse allograft infiltrates on chest radiograph",
"     </li>",
"     <li>",
"      Grade 2 -",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      between 200 and 300",
"     </li>",
"     <li>",
"      Grade 3 -",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &lt;200",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The scores are calculated on arrival in the intensive care unit (ICU) after lung transplantation, and again at 24, 48, and 72 hours. This system is most commonly used in patients with bilateral lung transplants. Further refinement of the criteria may include guidance on scoring patients with single transplants and use of additional time points at 6 and 12 hours after arrival in the ICU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/34\">",
"     34",
"    </a>",
"    ]. Recent studies have demonstrated that PGD 3 at 72 hours leads to the worst short and long term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is hoped that this classification system will be useful to accurately define the subset of patients with potentially poor outcomes who may benefit from early, aggressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PGD is a diagnosis of exclusion when declining oxygenation and diffuse pulmonary opacities in the transplanted lung(s) develop in the first 72 hours following transplant. The differential diagnosis of PGD includes pulmonary edema from volume overload or myocardial dysfunction, pneumonia, antibody mediated rejection, aspiration, pulmonary thromboembolism, and technical problems such as venous anastomosis occlusion. A general approach to the evaluation of postoperative hypoxemia is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=see_link\">",
"     \"Overview of the management of postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume status should be assessed, aiming for a central venous pressure of 7 mmHg or less or a pulmonary artery occlusion pressure (PAOP) of 10 mmHg or less, while maintaining adequate urine output, oxygen delivery, and systemic blood pressure. An echocardiogram may be helpful to assess left ventricular function. In patients with more severe PGD, pulmonary artery and central venous pressures may be elevated, making it more important to use PAOP to guide fluid management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main parameters used to differentiate pneumonia from PGD are presence of fever, elevation in white blood cell count, and positive culture results. All patients with suspected PGD should undergo fiberoptic bronchoscopy with bronchoalveolar lavage and protected specimen brushing, if available. Bacteria are the most common infectious agents in the immediate post-transplant period despite prophylactic antibiotics. In addition to culture of bronchoscopic specimens, blood cultures should be obtained and donor culture results reviewed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=see_link&amp;anchor=H604798#H604798\">",
"     \"Bacterial infections following lung transplantation\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antibody mediated rejection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperacute rejection is caused by preformed antibodies (eg, human leukocyte (HLA) antibodies or ABO isoagglutinins) and occurs in the first 24 hours after lung transplantation; acute antibody mediated rejection occurs after the first 24 hours. Hyperacute rejection is very rare in lung transplantation, probably related to use of sensitive pretransplant panel reactive antibody (PRA) testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When acute antibody mediated rejection is suspected, results of pretransplant panel reactive antibody (PRA) testing should be reviewed; a direct cross match between the donor and recipient should also be performed, preferably using flow cytometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/39\">",
"     39",
"    </a>",
"    ]. The risk of antibody mediated rejection increases with increasing PRA levels, particularly when PRA levels are over 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional diagnostic possibilities and their evaluation include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Computed tomography with pulmonary angiography may be helpful to assess for pulmonary embolism and to differentiate pleural (eg, pleural hemothorax) from pulmonary parenchymal disease.",
"     </li>",
"     <li>",
"      Thrombosis of the venous anastomosis should be suspected if one of the transplanted lungs appears opaque on plain chest radiograph. The most useful test to evaluate this possibility is a transesophageal echocardiogram.",
"     </li>",
"     <li>",
"      Aspiration is an uncommon cause of acute respiratory failure in the immediate postoperative period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of strategies have been developed to prevent PGD (",
"    <a class=\"graphic graphic_table graphicRef54028 \" href=\"mobipreview.htm?18/41/19101\">",
"     table 2",
"    </a>",
"    ). Strategies related to reducing the impact of lung ischemic time, optimizing reperfusion, and manipulating prostaglandin levels are discussed here. Hemodynamic management, hormone repletion, ventilator management, and donor lung preservation strategies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12425?source=see_link\">",
"     \"Lung transplantation: Deceased donor evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Limiting cold ischemia time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal and acceptable cold ischemic temperatures and times are not known. Most transplant centers use a storage temperature of 4 to 8&ordm;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/8\">",
"     8",
"    </a>",
"    ]. Ischemic times of up to eight hours are usually considered acceptable; however, conflicting data have been reported regarding whether longer ischemic times contribute to PGD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Risk factors'",
"    </a>",
"    above.) The decision to use lungs after ischemic times over eight hours should be made based on the evaluation of the risk factors in the lung donor (eg, age, clinical variables, smoking history) while also considering the overall status of the recipient. We have utilized lungs after up to 12 hours of cold preservation with acceptable results. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Methods of reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from animal models suggest that the pulmonary artery pressure during the initial 10 minutes of reperfusion is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. If the lung is rapidly reperfused, lung injury is increased, manifest as progressively more severe PGD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Gradual reintroduction of blood flow over a 10-minute period has been shown to reduce lung injury and improve function of the transplanted lung in animal models and is routine at many transplant centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models demonstrate better graft function when prostaglandin E1 (PGE1, alprostadil), is added to preservation solutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. This has led many clinical centers to use PGE1 as an additive to lung preservation solutions. The efficacy of this approach in humans is unclear given that controlled trials are lacking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5640?source=see_link\">",
"     \"Lung transplantation: Donor lung preservation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of prostaglandin use in animal models include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous administration of PGE1 to the recipient during the early phase of reperfusion reduced ischemia-reperfusion injury in a rat model of lung transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pretreatment of donor lungs with an aerosolized prostaglandin I2 (PGI2,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      ) ameliorated reperfusion injury in pigs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, inhaled nitric oxide (iNO) does not appear to prevent PGD. This was shown in a few small randomized trials, in which iNO did not improve oxygenation, formation of pulmonary edema, time to extubation, length of ICU stay, and 30-day mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main treatment strategy for PGD is supportive care. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific modalities that may be considered include inhaled nitric oxide and extracorporeal membrane oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although only evaluated in case series, inhaled nitric oxide (iNO) therapy appears to improve oxygenation, lower mean pulmonary artery pressure, and reduce the duration of mechanical ventilation compared with historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Theoretically, iNO improves ventilation-perfusion mismatch and decreases pulmonary artery pressures without affecting systemic pressures.",
"   </p>",
"   <p>",
"    We suggest using iNO in patients with severe PGD; the exact threshold for initiation of iNO is uncertain, but a rough guideline would be grade 3 PGD with refractory hypoxemia and elevated pulmonary artery pressures. The usual concentration of iNO is 10 to 20 ppm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methemoglobinemia, a side effect of iNO, occurs in about 6 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/54,55,57\">",
"     54,55,57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Extracorporeal membrane oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most lung transplant programs reserve extracorporeal membrane oxygenation (ECMO) for severe, life-threatening PGD (ie, a minority of patients with grade 3 PGD); ECMO may serve as a life-saving measure for adult lung transplant recipients with severe forms of PGD, who do not respond to maximal conventional treatment and a trial of iNO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/56,58-60\">",
"     56,58-60",
"    </a>",
"    ]. In this setting, ECMO may be the only way to provide the patient with adequate oxygenation and gas exchange while awaiting lung function recovery and avoiding the detrimental effects of aggressive ventilation and persistent hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. A registry review of 151 lung transplant recipients treated with ECMO for PGD found that 42 percent survived their hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/58\">",
"     58",
"    </a>",
"    ]. Among 28 patients with PGD managed with ECMO between 2001 and 2009, survivals at 30 days, 1 year, and 5 years were 82, 64, and 49 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=see_link\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Available data indicate that ECMO should be initiated within 24 hours of onset of severe PGD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/56,62,64\">",
"     56,62,64",
"    </a>",
"    ]. Complications related to ECMO include hemorrhage, renal failure, neurologic problems, hypotension, and sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/58\">",
"     58",
"    </a>",
"    ]. Improved technology and better understanding of patient physiology while on ECMO have significantly decreased complications related to this treatment and improved survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/65\">",
"     65",
"    </a>",
"    ]. A general discussion of outcomes among patients with acute respiratory failure managed at an ECMO center is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=see_link&amp;anchor=H3#H3\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\", section on 'Acute respiratory failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Venovenous ECMO is preferred over venoarterial in patients who do not require hemodynamic support, as it is associated with fewer complications such as bleeding or stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL STRATEGIES TO PREVENT OR TREAT PGD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several agents and strategies are under investigation for prevention or treatment of PGD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some transplant centers have expanded use of prostaglandin E1 and I2 from prevention of PGD to treatment for severe PGD, although clinical trial data are lacking. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Prevention'",
"    </a>",
"    above.) Prospective randomized trials are required to determine whether prostaglandin infusion is beneficial for the treatment of PGD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Surfactant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surfactant dysfunction has been shown to occur after ischemia-reperfusion injury of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Experimental studies in pigs have found that exogenous surfactant therapy improves pulmonary compliance and alveolar-arterial oxygen gradient after lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical case reports and an open label trial have also shown promising results using surfactant in patients with PGD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In addition, a randomized trial of 15 lung transplant recipients showed a benefit when exogenous surfactant was instilled into donor lungs before retrieval; post-transplant surfactant function and forced expiratory volume in one second were both improved relative to control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Complement inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement activation is thought to play a significant role in ischemia reperfusion injury following lung transplant. Soluble complement receptor-1 (sCR-1) inhibited complement activation and successfully prevented PGD in an animal model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/74\">",
"     74",
"    </a>",
"    ]. A multicenter randomized trial of sCR-1 versus placebo performed in 59 lung transplant recipients demonstrated better outcomes as measured by a shorter duration of mechanical ventilation and ICU stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/75\">",
"     75",
"    </a>",
"    ]. However, this strategy is still not used routinely after lung transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low tidal volume ventilation is also referred to as lung protective ventilation. The rationale for this approach is that smaller tidal volumes (eg, 6",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    and lower plateau pressures (eg, &le;30 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) are less likely to generate alveolar over distension, one of the principal causes of ventilator-associated lung injury (",
"    <a class=\"graphic graphic_table graphicRef57072 \" href=\"mobipreview.htm?9/5/9309\">",
"     table 3",
"    </a>",
"    ). Data are lacking regarding the use of this ventilatory strategy in the post-transplant patient, however evidence from other causes of acute lung injury suggests that it may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Platelet-activating factor antagonist (PAF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet activating factor (PAF) is produced by lung epithelial cells in response to hypoxia and is thought to contribute to PGD through neutrophil recruitment and increased vascular permeability. A clinical trial examining an antagonist of platelet-activating factor (PAF; BN 52021) randomly assigned 24 patients to either a high or low dose of antagonist or placebo in the flush solution and after reperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/76\">",
"     76",
"    </a>",
"    ]. The alveolar&ndash;arterial oxygen difference during the first 12 hours after reperfusion and chest X-ray score were better in the two groups receiving the antagonist, as compared with the control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene-based therapy offers the potential to genetically modify organs to withstand the stresses of the transplant process. Gene transfer has been achieved experimentally using vectors such as viruses to allow endobronchial transfer of several proteins of interest. As examples, transfer of soluble type 1 interleukin receptor, IL-10, and IkappaB suppressor genes have been shown to attenuate ischemia-reperfusion injury in animal models of lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. Optimization of gene delivery systems and diminished inflammatory response to the vectors are still important requirements to move this strategy to the clinical lung transplantation setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Preconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle of preconditioning is that tissues exposed to one insult can develop tolerance to a subsequent injury. Ischemic preconditioning has been shown to be effective in hepatic resection and in coronary artery bypass surgery, but its role in clinical lung transplantation remains unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Heme oxygenase pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective overexpression of heme oxygenase-1 confers protection against ischemia-reperfusion in experimental models; the mechanism remains poorly understood, but may involve the three products generated by the enzyme (biliverdin, carbon monoxide, and free iron) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/81\">",
"     81",
"    </a>",
"    ]. Future studies are required to determine the role of manipulation of this pathway in protection of the lung after reperfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     RETRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retransplantation for PGD is generally associated with a poor outcome and is avoided by most transplant centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/56,82\">",
"     56,82",
"    </a>",
"    ]. A review that included 23 patients retransplanted for PGD found significantly shorter survival compared with retransplantation for bronchiolitis obliterans syndrome or severe airway narrowing at the anastomotic site; at one year only about 30 percent of patients with retransplantation for PGD were still alive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PGD is responsible for significant early morbidity and mortality following lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/36\">",
"     36",
"    </a>",
"    ]. In a study of 255 lung transplants, the 30 day mortality rate for patients with and without PGD were 63 and 9 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, patients who survived PGD had a longer hospital length of stay and poorer lung function at one year compared with those without PGD.",
"   </p>",
"   <p>",
"    The ISHLT grading system for PGD has been studied to determine whether it is predictive of outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Grading system'",
"    </a>",
"    above.) Studies have found that the score at 48 hours correlates well with short and long term outcomes. In one study of 402 lung transplant recipients, severe (Grade 3) PGD at 48 hours was associated with an increased risk of short- and long-term mortality and increased length of hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/83\">",
"     83",
"    </a>",
"    ]. However, the PGD score on arrival to the ICU has not been as predictive as the score at later time points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/37\">",
"     37",
"    </a>",
"    ]. Instead, the change in",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    over the first 12 hours appears to be a better predictor of outcome than the initial PGD score. As an example, among 96 patients with a PGD score of 3 on arrival to the ICU, those with a 20 percent improvement in",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    over 12 hours had a better outcome than those who did not improve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     EFFECT ON CHRONIC REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most series have found that patients who survive PGD are at increased risk for subsequent development of chronic lung transplant rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. In a retrospective cohort study of 334 lung transplant recipients, the severity of initial PGD correlated with the risk of bronchiolitis obliterans syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/86\">",
"     86",
"    </a>",
"    ]. However, a previous single center study did not find such a relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/88\">",
"     88",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential explanation for this relationship comes from evidence suggesting that early inflammation associated with ischemia reperfusion (IR) injury promotes the development of alloimmunity and chronic human allograft rejection, manifest as bronchiolitis obliterans syndrome (BOS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36057/abstract/89\">",
"     89",
"    </a>",
"    ]. The degree of pro-inflammatory cytokine release after transplantation may have an important role in the interplay of innate and adaptive immune mechanisms that ultimately promote donor-specific alloimmunity predisposing to BOS. Hence, strategies to prevent IR injury have an important role not only in diminishing early post-transplant complications, but also in improving long-term outcomes after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary graft dysfunction (PGD) after lung transplantation represents a multifactorial injury to the transplanted lung(s) that develops in the first 72 hours after lung transplantation; the pathology is typical of acute lung injury rather than immunologic rejection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both cold ischemic storage and ischemia-reperfusion injury appear to contribute to PGD. Other contributors may include donor thromboembolism, recipient aspiration or pneumonia, and ventilator-associated lung injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The International Society of Heart Lung Transplantation has proposed a grading system for the classification of PGD based on the",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      ratio. The scores are calculated on arrival in the ICU after lung transplantation, and again at 24, 48, and 72 hours. The PGD scores may be useful prognostically. It is most commonly used in patients with bilateral lung transplants. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Grading system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strategies to prevent PGD include use of adequate donor lung selection and optimization of preservation, storage, and reperfusion techniques. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5640?source=see_link\">",
"       \"Lung transplantation: Donor lung preservation\"",
"      </a>",
"      .) We suggest not using inhaled nitric oxide (iNO) to prevent PGD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with PGD less than grade 3 severity or with grade 3 severity and normal pulmonary artery pressures, we suggest conventional supportive treatment, using lung protective ventilation and optimal fluid management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among those with more severe grade 3 PGD (ie, persistent difficulty with oxygenation and elevated pulmonary artery pressures), we suggest adding iNO at a concentration of 10 to 20 ppm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Nitric oxide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe grade 3 PGD who don't respond adequately to optimal ventilator and fluid management and iNO, we suggest initiating extracorporeal membrane oxygenation (ECMO) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). ECMO has a greater likelihood of success when started within 24 hours of the onset of severe PGD. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Extracorporeal membrane oxygenation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retransplantation for PGD is generally associated with a poor outcome. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Retransplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PGD appears to be a risk factor for subsequent development of chronic lung transplant rejection. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Effect on chronic rejection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/1\">",
"      Christie JD, Bavaria JE, Palevsky HI, et al. Primary graft failure following lung transplantation. Chest 1998; 114:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/2\">",
"      Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/3\">",
"      King RC, Binns OA, Rodriguez F, et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/4\">",
"      Christie JD, Sager JS, Kimmel SE, et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/5\">",
"      Khan SU, Salloum J, O'Donovan PB, et al. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response. Chest 1999; 116:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/6\">",
"      Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005. J Heart Lung Transplant 2005; 24:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/7\">",
"      de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/8\">",
"      de Perrot M, Bonser RS, Dark J, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 2005; 24:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/9\">",
"      Fisher AJ, Donnelly SC, Hirani N, et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001; 163:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/10\">",
"      Kaneda H, Waddell TK, de Perrot M, et al. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006; 6:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/11\">",
"      Tremblay LN, Yamashiro T, DeCampos KN, et al. Effect of hypotension preceding death on the function of lungs from donors with nonbeating hearts. J Heart Lung Transplant 1996; 15:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/12\">",
"      Rostron AJ, Avlonitis VS, Cork DM, et al. Hemodynamic resuscitation with arginine vasopressin reduces lung injury after brain death in the transplant donor. Transplantation 2008; 85:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/13\">",
"      Avlonitis VS, Wigfield CH, Golledge HD, et al. Early hemodynamic injury during donor brain death determines the severity of primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/14\">",
"      Thabut G, Mal H, Cerrina J, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med 2005; 171:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/15\">",
"      Fiser SM, Kron IL, Long SM, et al. Influence of graft ischemic time on outcomes following lung transplantation. J Heart Lung Transplant 2001; 20:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/16\">",
"      Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant 1999; 18:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/17\">",
"      Fisher AB, Al-Mehdi AB, Muzykantov V. Activation of endothelial NADPH oxidase as the source of a reactive oxygen species in lung ischemia. Chest 1999; 116:25S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/18\">",
"      De Perrot M, Sekine Y, Fischer S, et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 2002; 165:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/19\">",
"      Covarrubias M, Ware LB, Kawut SM, et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/20\">",
"      Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998; 102:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/21\">",
"      Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/22\">",
"      Ivey CL, Williams FM, Collins PD, et al. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8. J Clin Invest 1995; 95:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/23\">",
"      Sato Y, Hogg JC, English D, van Eeden SF. Endothelin-1 changes polymorphonuclear leukocytes' deformability and CD11b expression and promotes their retention in the lung. Am J Respir Cell Mol Biol 2000; 23:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/24\">",
"      Zwacka RM, Zhang Y, Halldorson J, et al. CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 1997; 100:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/25\">",
"      Eppinger MJ, Jones ML, Deeb GM, et al. Pattern of injury and the role of neutrophils in reperfusion injury of rat lung. J Surg Res 1995; 58:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/26\">",
"      Fiser SM, Tribble CG, Long SM, et al. Lung transplant reperfusion injury involves pulmonary macrophages and circulating leukocytes in a biphasic response. J Thorac Cardiovasc Surg 2001; 121:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/27\">",
"      Eppinger MJ, Deeb GM, Bolling SF, Ward PA. Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol 1997; 150:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/28\">",
"      de Perrot, M, Young, K, Imai, Y, et al. Involvement of donor T cells in the regulation of ischemia-reperfusion injury during lung transplantation [abstract]. J Heart Lung Transplant 2002; 21:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/29\">",
"      Whitson BA, Nath DS, Johnson AC, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006; 131:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/30\">",
"      Oto T, Excell L, Griffiths AP, et al. The implications of pulmonary embolism in a multiorgan donor for subsequent pulmonary, renal, and cardiac transplantation. J Heart Lung Transplant 2008; 27:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/31\">",
"      Barr ML, Kawut SM, Whelan TP, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: recipient-related risk factors and markers. J Heart Lung Transplant 2005; 24:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/32\">",
"      Fang A, Studer S, Kawut SM, et al. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2011; 139:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/33\">",
"      Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/34\">",
"      Oto T, Griffiths AP, Levvey BJ, et al. Definitions of primary graft dysfunction after lung transplantation: differences between bilateral and single lung transplantation. J Thorac Cardiovasc Surg 2006; 132:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/35\">",
"      Christie JD, Bellamy S, Ware LB, et al. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2010; 29:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/36\">",
"      Arcasoy SM, Fisher A, Hachem RR, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant 2005; 24:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/37\">",
"      Prekker ME, Herrington CS, Hertz MI, et al. Early Trends in PaO(2)/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction. Chest 2007; 132:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/38\">",
"      Christie, JD, Ahya, VN, Sager, JS, et al. ISHLT PGD grade predicts differential mortality following lung transplantation. J Heart Lung Transplant 2005; 24 Suppl 2:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/39\">",
"      Masson E, Stern M, Chabod J, et al. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant 2007; 26:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/40\">",
"      Shah AS, Nwakanma L, Simpkins C, et al. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg 2008; 85:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/41\">",
"      Pierre AF, DeCampos KN, Liu M, et al. Rapid reperfusion causes stress failure in ischemic rat lungs. J Thorac Cardiovasc Surg 1998; 116:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/42\">",
"      Clark SC, Sudarshan C, Khanna R, et al. Controlled reperfusion and pentoxifylline modulate reperfusion injury after single lung transplantation. J Thorac Cardiovasc Surg 1998; 115:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/43\">",
"      Bhabra MS, Hopkinson DN, Shaw TE, et al. Controlled reperfusion protects lung grafts during a transient early increase in permeability. Ann Thorac Surg 1998; 65:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/44\">",
"      Halldorsson A, Kronon M, Allen BS, et al. Controlled reperfusion after lung ischemia: implications for improved function after lung transplantation. J Thorac Cardiovasc Surg 1998; 115:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/45\">",
"      Chiang CH, Wu K, Yu CP, et al. Protective agents used as additives in University of Wisconsin solution to promote protection against ischaemia-reperfusion injury in rat lung. Clin Sci (Lond) 1998; 95:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/46\">",
"      Chiang CH, Wu K, Yu CP, et al. Hypothermia and prostaglandin E(1) produce synergistic attenuation of ischemia-reperfusion lung injury. Am J Respir Crit Care Med 1999; 160:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/47\">",
"      Naka Y, Roy DK, Liao H, et al. cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ Res 1996; 79:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/48\">",
"      Levin G, Duffin KL, Obukowicz MG, et al. Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J 2002; 365:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/49\">",
"      de Perrot M, Fischer S, Liu M, et al. Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti-inflammatory cytokines. Transplantation 2001; 72:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/50\">",
"      Wittwer T, Franke UF, Ochs M, et al. Inhalative pre-treatment of donor lungs using the aerosolized prostacyclin analog iloprost ameliorates reperfusion injury. J Heart Lung Transplant 2005; 24:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/51\">",
"      Meade M, Granton JT, Matte-Martyn A, et al. A randomized trial of inhaled nitric oxide to prevent reperfusion injury following lung transplantation. J Heart Lung Transplant 2001; 20:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/52\">",
"      Botha P, Jeyakanthan M, Rao JN, et al. Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2007; 26:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/53\">",
"      Perrin G, Roch A, Michelet P, et al. Inhaled nitric oxide does not prevent pulmonary edema after lung transplantation measured by lung water content: a randomized clinical study. Chest 2006; 129:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/54\">",
"      Date H, Triantafillou AN, Trulock EP, et al. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996; 111:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/55\">",
"      Kemming GI, Merkel MJ, Schallerer A, et al. Inhaled nitric oxide (NO) for the treatment of early allograft failure after lung transplantation. Munich Lung Transplant Group. Intensive Care Med 1998; 24:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/56\">",
"      Shargall Y, Guenther G, Ahya VN, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J Heart Lung Transplant 2005; 24:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/57\">",
"      Adatia I, Lillehei C, Arnold JH, et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994; 57:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/58\">",
"      Fischer S, Bohn D, Rycus P, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: analysis of the Extracorporeal Life Support Organization (ELSO) registry. J Heart Lung Transplant 2007; 26:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/59\">",
"      Dahlberg PS, Prekker ME, Herrington CS, et al. Medium-term results of extracorporeal membrane oxygenation for severe acute lung injury after lung transplantation. J Heart Lung Transplant 2004; 23:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/60\">",
"      Bermudez CA, Adusumilli PS, McCurry KR, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: long-term survival. Ann Thorac Surg 2009; 87:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/61\">",
"      Meyers BF, Sundt TM 3rd, Henry S, et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000; 120:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/62\">",
"      Fiser SM, Kron IL, McLendon Long S, et al. Early intervention after severe oxygenation index elevation improves survival following lung transplantation. J Heart Lung Transplant 2001; 20:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/63\">",
"      Hartwig MG, Walczak R, Lin SS, Davis RD. Improved survival but marginal allograft function in patients treated with extracorporeal membrane oxygenation after lung transplantation. Ann Thorac Surg 2012; 93:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/64\">",
"      Glassman LR, Keenan RJ, Fabrizio MC, et al. Extracorporeal membrane oxygenation as an adjunct treatment for primary graft failure in adult lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/65\">",
"      Diaz-Guzman E, Davenport DL, Zwischenberger JB, Hoopes CW. Lung function and ECMO after lung transplantation. Ann Thorac Surg 2012; 94:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/66\">",
"      Ware LB, Fang X, Wang Y, et al. Selected contribution: mechanisms that may stimulate the resolution of alveolar edema in the transplanted human lung. J Appl Physiol 2002; 93:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/67\">",
"      Ochs M, Nenadic I, Fehrenbach A, et al. Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion. Am J Respir Crit Care Med 1999; 160:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/68\">",
"      Andrade RS, Solien EE, Wangensteen OD, et al. Surfactant dysfunction in lung preservation. Transplantation 1995; 60:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/69\">",
"      Hohlfeld JM, Str&uuml;ber M, Ahlf K, et al. Exogenous surfactant improves survival and surfactant function in ischaemia-reperfusion injury in minipigs. Eur Respir J 1999; 13:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/70\">",
"      Koletsis E, Chatzimichalis A, Fotopoulos V, et al. Donor lung pretreatment with surfactant in experimental transplantation preserves graft hemodynamics and alveolar morphology. Exp Biol Med (Maywood) 2003; 228:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/71\">",
"      Kermeen FD, McNeil KD, Fraser JF, et al. Resolution of severe ischemia-reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J Heart Lung Transplant 2007; 26:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/72\">",
"      Amital, A, Shitrit, D, Raviv, Y, et al. The use of surfactant in lung transplantation: A randomized control pilot study. J Heart Lung Transplant 2006; 25 Suppl 2:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/73\">",
"      Str&uuml;ber M, Fischer S, Niedermeyer J, et al. Effects of exogenous surfactant instillation in clinical lung transplantation: a prospective, randomized trial. J Thorac Cardiovasc Surg 2007; 133:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/74\">",
"      Pierre AF, Xavier AM, Liu M, et al. Effect of complement inhibition with soluble complement receptor 1 on pig allotransplant lung function. Transplantation 1998; 66:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/75\">",
"      Keshavjee S, Davis RD, Zamora MR, et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 2005; 129:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/76\">",
"      Wittwer T, Grote M, Oppelt P, et al. Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. J Heart Lung Transplant 2001; 20:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/77\">",
"      Ishiyama T, Dharmarajan S, Hayama M, et al. Inhibition of nuclear factor kappaB by IkappaB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Thorac Cardiovasc Surg 2005; 130:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/78\">",
"      Tagawa T, Dharmarajan S, Hayama M, et al. Endobronchial gene transfer of soluble type I interleukin-1 receptor ameliorates lung graft ischemia-reperfusion injury. Ann Thorac Surg 2004; 78:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/79\">",
"      Martins S, de Perrot M, Imai Y, et al. Transbronchial administration of adenoviral-mediated interleukin-10 gene to the donor improves function in a pig lung transplant model. Gene Ther 2004; 11:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/80\">",
"      Fedalen PA, Piacentino V 3rd, Jeevanandam V, et al. Pharmacologic pre-conditioning and controlled reperfusion prevent ischemia-reperfusion injury after 30 minutes of hypoxia/ischemia in porcine hearts. J Heart Lung Transplant 2003; 22:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/81\">",
"      Otterbein LE, Choi AM. Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol 2000; 279:L1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/82\">",
"      Aigner C, Jaksch P, Taghavi S, et al. Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant 2008; 27:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/83\">",
"      Prekker ME, Nath DS, Walker AR, et al. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2006; 25:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/84\">",
"      Fiser SM, Tribble CG, Long SM, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/85\">",
"      Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007; 26:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/86\">",
"      Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/87\">",
"      Bharat A, Kuo E, Steward N, et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008; 86:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/88\">",
"      Fisher AJ, Wardle J, Dark JH, Corris PA. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2002; 21:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36057/abstract/89\">",
"      Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007; 83:150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4663 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36057=[""].join("\n");
var outline_f35_13_36057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pretransplant factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Retrieval/cold storage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ischemia/reperfusion injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Post-transplant factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Grading system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Limiting cold ischemia time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Methods of reperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Extracorporeal membrane oxygenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      EXPERIMENTAL STRATEGIES TO PREVENT OR TREAT PGD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Surfactant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Complement inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Platelet-activating factor antagonist (PAF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Preconditioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Heme oxygenase pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      RETRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      EFFECT ON CHRONIC REJECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4663|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/61/4063\" title=\"figure 1\">",
"      Primary graft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/6/18539\" title=\"table 1\">",
"      Primary graft dysfn severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/41/19101\" title=\"table 2\">",
"      Lung transplant donor management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/5/9309\" title=\"table 3\">",
"      Low tidal volume vent",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3994?source=related_link\">",
"      Evaluation and treatment of acute lung transplant rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3688?source=related_link\">",
"      Induction immunosuppression following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12425?source=related_link\">",
"      Lung transplantation: Deceased donor evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5640?source=related_link\">",
"      Lung transplantation: Donor lung preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=related_link\">",
"      Lung transplantation: Procedure and postoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_13_36058="The preparticipation sports examination in children and adolescents";
var content_f35_13_36058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The preparticipation sports examination in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/13/36058/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36058/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/13/36058/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36058/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36058/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/13/36058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/13/36058/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/13/36058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 million children and adolescents participate in organized sports in the United States. The standard of care is that these athletes have a preparticipation physical evaluation (PPE) before the season begins. In addition, the 2010 consensus guidelines for the PPE suggest a PPE for all children, even those who do not participate in organized sports, as an opportunity to promote health and fitness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary goal of the PPE is to maximize safe participation by children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ]. The preparticipation sports examination is not designed to be the comprehensive adolescent evaluation recommended by the American Medical Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19000?source=see_link\">",
"     \"Guidelines for adolescent preventive services\"",
"    </a>",
"    .) Conversely, the comprehensive health maintenance visit should not substitute for the PPE unless it includes the necessary components of the sports history and physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF THE PREPARTICIPATION SPORTS EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the preparticipation sports examination are to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maximize safe participation by children and adolescents",
"     </li>",
"     <li>",
"      Identify medical problems with risks of life-threatening complications during participation (eg, hypertrophic cardiomyopathy)",
"     </li>",
"     <li>",
"      Identify conditions that require a treatment plan before or during participation (eg, hypertension)",
"     </li>",
"     <li>",
"      Identify and rehabilitate old musculoskeletal injuries",
"     </li>",
"     <li>",
"      Identify and treat conditions that interfere with performance (eg, exercise-induced bronchospasm)",
"     </li>",
"     <li>",
"      Remove unnecessary restrictions on participation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2010 consensus guidelines for the preparticipation physical evaluation (PPE) suggest that physicians consider including questions on topics such as drug use, sexual activity, violence, and mental health, which pose more serious threats to the health of teens than do injuries incurred during sports participation.",
"   </p>",
"   <p>",
"    In the author's experience, these questions are important to ask but not necessarily in the context of the PPE. Considering that the PPE substitutes for the annual comprehensive health evaluation for 30 to 78 percent of adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], it may be appropriate to explore some of these areas if the PPE occurs in the context of the private office, the parents and youth know in advance what the visit will encompass, and there are resources to meet the needs of the youth if",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    screens positive for health risk behaviors. However, in the context of a directed, or station-approach, PPE, the setting may not afford the confidentiality that the discussion of health risk behaviors requires, and the examiner may not have the skills, time, or resources to address specific health risks (eg, alcohol use, mental health). If time and resources are limited, the examiner should perform the necessary components for clearance to participate and recommend a subsequent comprehensive evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Establishing mechanisms wherein teens receive annual comprehensive health maintenance visits and have PPEs is a priority. In a school-based clinic with which the author is familiar, for example, the athletes complete a comprehensive questionnaire addressing psychosocial issues as part of the PPE. If a problem is identified that is outside the scope of the PPE, the athlete is asked to return to the clinic for follow-up. A similar questionnaire could be used when the PPE is performed by multiple examiners; the athlete is referred back to his or her primary care provider when problems are identified.",
"   </p>",
"   <p>",
"    The PPE should take place four to six weeks before the season starts, permitting time to evaluate and treat medical problems",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rehabilitate musculoskeletal injuries before sports participation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Conditions that limit participation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children and adolescents with chronic medical conditions can participate in a sport at some level after appropriate evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6\">",
"     6",
"    </a>",
"    ]. Some conditions, such as cervical spine stenosis, restrict participation in contact sports or may have qualified restrictions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Guidelines for sports participation for children with various medical conditions are provided in the full text of reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6\">",
"     6",
"    </a>",
"    ]. Guidelines for sports participation for children and adolescents with sickle cell trait are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13960?source=see_link&amp;anchor=H14#H14\">",
"     \"Sickle cell trait\", section on 'Risk for sudden death and athletic participation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A limited number of medical conditions exist for which participation in sports activity or exercise is associated with life-threatening complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .) Sudden death in the young athlete occurs with an estimated prevalence of between 1:100,000 and 1:300,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The risk of sudden death is disproportionately higher in males. In a series of 134 cardiovascular sudden deaths among athletes (1985-1995), 90 percent occurred in males and the median age was 17 years (range 12 to 49 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cardiovascular conditions",
"      </strong>",
"      &ndash; Cardiovascular conditions causing sudden death in young athletes include (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39945?source=see_link&amp;anchor=H192520700#H192520700\">",
"       \"Sudden cardiac arrest and death in children\", section on 'Etiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link&amp;anchor=H7#H7\">",
"       \"Risk of sudden cardiac death in athletes\", section on 'Etiology of sudden death'",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/8,10\">",
"       8,10",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypertrophic cardiomyopathy (HCM) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Coronary artery anomalies (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=see_link\">",
"       \"Congenital and pediatric coronary artery abnormalities\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Commotio cordis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12101?source=see_link&amp;anchor=H4609681#H4609681\">",
"       \"Commotio cordis\", section on 'Clinical manifestations, diagnosis, and outcomes'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myocarditis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aortic rupture (Marfan syndrome) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular hypertrophy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32106?source=see_link&amp;anchor=H1492598#H1492598\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Long QT syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features of congenital long QT syndrome\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wolff-Parkinson-White syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=see_link&amp;anchor=H10#H10\">",
"       \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aortic stenosis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link&amp;anchor=H5#H5\">",
"       \"Valvar aortic stenosis in children\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Life-threatening cardiovascular diseases in young athletes are rare. Most athletes who die suddenly have no symptoms of life-threatening cardiovascular disease, and the PPE is not efficient in detecting them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. However, athletes suspected of having these conditions on the basis of historical or physical findings must not participate until further evaluation by a cardiologist.",
"    <br/>",
"    <br/>",
"    Sudden cardiac death during exercise in patients with mitral valve prolapse is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17719?source=see_link\">",
"     \"Arrhythmic complications of mitral valve prolapse\"",
"    </a>",
"    .) Athletes with mitral valve prolapse can participate in all competitive sports unless the following exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of syncope documented to be arrhythmogenic in origin.",
"     </li>",
"     <li>",
"      A family history of sudden death associated with mitral valve prolapse.",
"     </li>",
"     <li>",
"      Repetitive forms of supraventricular and ventricular arrhythmias, particularly if exaggerated by exercise.",
"     </li>",
"     <li>",
"      Moderate to marked mitral regurgitation.",
"     </li>",
"     <li>",
"      Prior embolic event.",
"      <br/>",
"      <br/>",
"      Athletes with mitral valve prolapse and any of the above symptoms can participate in only low-intensity sports (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"mobipreview.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Uncontrolled stage 2 hypertension",
"      </strong>",
"      &ndash; Hypertension (systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic blood pressure [BP] &ge;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile for gender, age, and height) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"mobipreview.htm?7/45/7894\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"mobipreview.htm?7/46/7910\">",
"       table 2",
"      </a>",
"      ) is associated with an increased risk for sudden death and complex ventricular arrhythmias. However, hypertension has not been implicated as cause of sudden cardiac death in young, competitive athletes. It is recommended that uncontrolled stage 2 hypertension (systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99",
"      <sup>",
"       th",
"      </sup>",
"      percentile plus 5 mmHg) or end-organ damage (eg, retinal, renal, or cardiac changes) requires exclusion from sports participation and highly static activities (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"mobipreview.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ) until it is better controlled [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. However, this recommendation is based on expert opinion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link&amp;anchor=H4#H4\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Severity'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of hypertension in children and adolescents\", section on 'Sports participation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fever",
"      </strong>",
"      &ndash; Children and adolescents with fever should be restricted from participation because fever may accompany myocarditis or other infections that can make exercise dangerous. In addition, fever increases the risk of heat illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10234?source=see_link\">",
"       \"Heat stroke in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21878?source=see_link\">",
"       \"Heat illness (other than heat stroke) in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Conditions that require a treatment plan before or during exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to cardiovascular abnormalities, numerous other medical conditions should be identified before clearance for sports participation because the conditions are associated with increased risk of adverse outcome or injury if left untreated. Examples of these conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise-induced bronchoconstriction (EIB) occurs in athletes at a prevalence similar to that of the general population (9 to 15 percent), yet it may be unrecognized in the young athlete [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Pulmonary disease accounts for 2 percent of sudden death in sports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/20\">",
"       20",
"      </a>",
"      ]. EIB can be treated with pre-exercise medication in most patients and is not a reason to avoid exercise. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=see_link\">",
"       \"Exercise-induced bronchoconstriction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most clinicians rely on a history of allergic rhinitis or other symptoms of asthma or EIB to make the diagnosis of EIB. However, neither the standard history nor the physical examination is accurate in predicting who will have EIB when compared with formal exercise testing and pulmonary function tests [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/19\">",
"       19",
"      </a>",
"      ]. In one study of 256 high school athletes, results of a screening history (ie, symptoms or history of asthma, EIB, and allergic rhinitis) and physical examination were compared with the gold standard of exercise testing and spirometry in the diagnosis of EIB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/19\">",
"       19",
"      </a>",
"      ]. EIB was diagnosed in 9.4 percent of the athletes. The screening evaluation detected only 56 percent of the athletes who had abnormal exercise challenge, and among those with a positive screening test, only 13 percent had EIB by exercise challenge. Until a better screening instrument is developed, physicians must continue to diagnose and treat asthma and attempt to diagnose and treat EIB in those without asthma based upon the history and physical examination, aided by spirometry as indicated, with the limitations discussed above. The use of postexercise spirometry in the routine PPE is not recommended.",
"     </li>",
"     <li>",
"      Hypertension, unless uncontrolled stage 2 hypertension (systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99",
"      <sup>",
"       th",
"      </sup>",
"      percentile plus 5 mmHg) (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"mobipreview.htm?7/45/7894\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"mobipreview.htm?7/46/7910\">",
"       table 2",
"      </a>",
"      ) or associated with end organ damage or heart disease, should not preclude sports participation. However, it is important to detect and initiate a treatment plan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. The treating clinician and the athlete should be aware that the use of diuretics and beta blockers has been prohibited by some athletic governing bodies; the treatment plan may need to be modified to permit participation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/16\">",
"       16",
"      </a>",
"      ]. The athlete should be counseled regarding the need to avoid exogenous androgens, growth hormone, and many nutrition supplements (eg, those that contain stimulants such as ephedrine). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link&amp;anchor=H4#H4\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Severity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eating disorders (eg, anorexia nervosa, bulimia nervosa, and eating disorder not otherwise specified) can manifest as excess exercise and malnutrition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .) Persistent exercise in the malnourished amenorrheic female athlete can cause short- and long-term consequences. Recommendations for exercise restriction need to be made as part of the PPE.",
"      <br/>",
"      <br/>",
"      For example, for female athletes who are between 85 and 90 percent of their estimated ideal body weight (IBW), have been losing weight, and have developed amenorrhea or oligomenorrhea related to the weight loss, the author suggests reducing training by one-half to one-third (eg, running 10 to 12 miles per week instead of 20) and adding 250 to 500",
"      <span class=\"nowrap\">",
"       kcal/d",
"      </span>",
"      with follow-up in two weeks to recheck weight and other vital signs. If the weight is improved then training volume could be increased again incrementally back up to full training with continued increase in calorie intake until the athlete maintains weight in the 90 to 100 percent estimate IBW range.",
"      <br/>",
"      <br/>",
"      The author usually restricts exercise if the athlete&rsquo;s weight is less than 85 percent of estimated IBW. However, there are exceptions. As an example, the mean estimated IBW for elite ballerinas has been reported to be 85 to 87 percent of estimated IBW [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/22\">",
"       22",
"      </a>",
"      ]. So, for some athletes with weights less than 85 percent of estimated IBW, the author may suggest continued exercise as long as they are followed for slow weight increases or weight stability.",
"     </li>",
"     <li>",
"      Some form of regular exercise is likely to be beneficial in most children and adolescents with diabetes mellitus. However, modifications in the pre-exercise insulin dose and additional glucose monitoring are necessary.",
"     </li>",
"     <li>",
"      Athletes at risk of heat illness (",
"      <a class=\"graphic graphic_table graphicRef73292 \" href=\"mobipreview.htm?2/14/2285\">",
"       table 3",
"      </a>",
"      ) should follow guidelines for appropriate clothing, fluid intake, heat acclimatization, adjustment of activity level for heat and humidity levels, and timing of practices. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10234?source=see_link\">",
"       \"Heat stroke in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21878?source=see_link\">",
"       \"Heat illness (other than heat stroke) in children\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Whether or not they are at risk of heat illness, athletes should consume fluid two hours before prolonged exercise and every 20 minutes during activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/23\">",
"       23",
"      </a>",
"      ]. Electrolyte replacement drinks (ie, sports drinks) are recommended after the first hour of prolonged exercise. The volume of intake varies according to the athlete's weight:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      40 kg &ndash; 500 mL (18 ounces) two hours before prolonged exercise and 150 mL (5 ounces) every 20 minutes during activity",
"     </li>",
"     <li>",
"      60 kg &ndash; 750 mL (25 ounces) two hours before prolonged exercise and 250 mL (9 ounces) every 20 minutes during activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concussion &ndash; There is no evidence-based guideline regarding return to play for child athletes (ie, 5- to 12-year-olds) following sports-related concussion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/24\">",
"       24",
"      </a>",
"      ]. There is more evidence in the 14- to 18-year-old group; however, there are still no evidence-based guidelines. Regardless of age, no symptomatic athlete can be cleared for sports activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/25\">",
"       25",
"      </a>",
"      ]. More conservative management is recommended for the pediatric age group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. A stepwise exertion protocol has been published for progression back to sports once the athlete is asymptomatic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/24\">",
"       24",
"      </a>",
"      ]. For the young athlete with repeated concussions, the decision to return to contact sports should be based on the number of concussions, the mechanism of previous concussions, the duration of recovery, and the time in between injuries. Worrisome signs are prolonged recovery, shorter intervals between concussions, and progressively less force to cause a concussion. For patients with worrisome signs, consideration should be given to choosing a sport with less risk of head injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/25,27\">",
"       25,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link&amp;anchor=H14#H14\">",
"       \"Concussion and mild traumatic brain injury\", section on 'Sequelae'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Musculoskeletal injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying and fully rehabilitating old musculoskeletal injuries has the greatest yield for identifying problems that will interfere with subsequent performance because injuries are common among athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Previous injury is the strongest predictor of sports injury (odds ratio [OR] 9.4, 95% CI 2.8-31.6 in one study of 182 healthy young adult athletes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/30\">",
"     30",
"    </a>",
"    ]. Musculoskeletal injuries requiring medical attention are reported by 20 percent of high school athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previous musculoskeletal injuries can have residua, such as decreased flexibility and strength related to inadequate rehabilitation, the demands of the sport, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/3,32\">",
"     3,32",
"    </a>",
"    ]. Players with injuries to an extremity are more likely to injure that extremity during the season than an extremity that has not been injured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/30,33-35\">",
"     30,33-35",
"    </a>",
"    ]. Proper rehabilitation can lead to lower injury rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The athlete's history of previous injury should draw the clinician's attention to assess for residual effects. In addition to providing a plan for rehabilitating strength, endurance, and proprioceptive and flexibility deficits, the clinician should provide the athlete with a plan for returning to play. The athlete is at risk of reinjury and delayed recovery if he or she returns to competition too soon. Training errors, such as too-rapid increases in pace, distance, repetitions, or",
"    <span class=\"nowrap\">",
"     weight/resistance,",
"    </span>",
"    are the most common factor in overuse injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Unnecessary restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another goal of the PPE is to remove unnecessary restriction on participation in sports or an exercise program. Unnecessary restriction can be imposed on children and adolescents because they are believed to have cardiac disease, because appropriate restrictions are not given an end-point, or because of concerns about complications that can be avoided with proper preventive therapy. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of the morbidity of cardiac non-disease identified 93 seventh- to ninth-grade students who had \"something wrong with their hearts\" according to school records [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/39\">",
"       39",
"      </a>",
"      ]. After pediatric cardiology evaluation, 75 of these 93 students (81 percent) were found to have no cardiac disease, yet 30 of these 75 students (40 percent) had activity restrictions ranging from being homebound to being able to participate in physical education classes but not competitive sports.",
"     </li>",
"     <li>",
"      Adolescent athletes with Osgood-Schlatter disease report stopping training and sports participation for months, and this may be with clinician advice. However, Osgood-Schlatter disease is a common problem and, although painful, should result in little if any restriction from sports activity when managed appropriately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12392?source=see_link\">",
"       \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The author has encountered obese patients in his practice who were advised not to play football until they lost weight because of concern that they were at risk for heat injury. Obesity is a risk factor for heat injury, and acclimatization is indicated in preparation for summer practices; however, exercise is an important component of obesity management, and restricting exercise is contraindicated in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GUIDELINES FOR PREPARTICIPATION SPORTS EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Consensus guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Family Physicians, American Academy of Pediatrics, American College of Sports Medicine, American Medical Society for Sports Medicine, American Orthopaedic Society for Sports Medicine, and American Osteopathic Academy for Sports Medicine have published guidelines for physicians to follow during the preparticipation physical evaluation (PPE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Heart Association (AHA) and the European Society of Cardiology have specific recommendations for preparticipation cardiovascular screening of competitive athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. However, the guidelines are not applied consistently. The AHA guidelines, for example, recommend that the PPE include certain questions to screen for increased risk of sudden cardiac death and be performed by a healthcare worker with the requisite training, medical skills, and background to reliably obtain a detailed cardiovascular history, perform a physical examination, and recognize heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In 2007, only 17 percent of US state high school athletic association preparticipation evaluation forms contained all of the elements recommended by the 2005 consensus guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examiners who perform the PPE must be able to accurately evaluate the musculoskeletal system. A majority of pediatric healthcare providers conduct PPEs, yet a minority has received training in sports medicine or the performance of these examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/44\">",
"     44",
"    </a>",
"    ]. Deficits in training in the management of common musculoskeletal injuries have been identified for current and recent residents in physiatry, family practice, pediatrics, and medicine-pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Clinicians who have deficits in the assessment and treatment of common musculoskeletal injuries should refer athletes who are found to have pain or other limitations in the screening musculoskeletal portion of the PPE. Similar to cardiovascular screening, inadequate musculoskeletal screening can occur if standardized medical forms do not contain the appropriate questions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AHA recommends that a history and physical examination be performed every two years during sports participation, with an interim history taken in the intervening years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/40\">",
"     40",
"    </a>",
"    ]. Most sports medicine clinicians recommend that the PPE be conducted before each new level of participation (eg, middle school, junior high, high school, and college), with yearly updates of the history and targeted physical examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ]. Requirements for the frequency of PPE vary by state, but most state high school athletic associations require annual evaluations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two common methods of conducting the PPE are the office setting, in which one clinician conducts the entire examination, and the station approach, in which the athlete goes through a series of stations, usually organ- or region-specific, and is examined by multiple examiners. Each method has advantages and disadvantages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination in the office setting by the athlete's primary care provider has the advantages of privacy, continuity of care, and the provider's knowledge of past medical and family history. However, the complete examination is time-consuming and costly. In addition, if the provider has not had PPE training, the health maintenance visit may be substituted for the PPE and may not adequately focus on the necessary components of the PPE.",
"   </p>",
"   <p>",
"    The station approach is time-efficient, sports-oriented, and inexpensive, and has a high yield for identifying abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/50\">",
"     50",
"    </a>",
"    ]. However, it may not provide for continuity of care. The station approach commonly is performed by volunteer physicians, usually at no cost to the athlete. It may be, and often is, the only health assessment for athletes without health insurance.",
"   </p>",
"   <p>",
"    One study compared single (n = 170 students) versus multiple examiners (n = 752 students) for high school athletes in Georgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/50\">",
"     50",
"    </a>",
"    ]. The multiple examiners found more mean abnormalities per student than did the single examiners (1.1 versus 0.2) and recommended further evaluation for more students before clearance for participation (6.4 versus 2.4 percent). Further evaluation was recommended for cardiac or musculoskeletal abnormalities, or for past history of heat illness or head, bone, or joint injury. None of the students examined by a single examiner was restricted from participation compared with three of the students examined by multiple examiners.",
"   </p>",
"   <p>",
"    The author prefers the office setting if the clinician has had training in conducting a PPE and the station approach if the clinicians involved have areas of special interest, such as cardiology or orthopedic surgery, but are not specifically trained in the PPE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMPONENTS OF THE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preparticipation physical evaluation (PPE) includes a targeted medical and family history and a targeted physical examination, with particular emphasis on the musculoskeletal and cardiovascular systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Evaluation forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Family Physicians, American Academy of Pediatrics, American College of Sports Medicine, American Medical Society for Sports Medicine, American Orthopaedic Society for Sports Medicine, and American Osteopathic Academy of Sports Medicine have endorsed a standardized preparticipation athletic evaluation form that addresses important aspects of the history and examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1,51\">",
"     1,51",
"    </a>",
"    ]. It can be downloaded from the",
"    <a class=\"external\" href=\"file://practice.aap.org/content.aspx?aID=2956\">",
"     American Academy of Pediatrics",
"    </a>",
"    HYPERLINK.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history is the most sensitive and specific component of the PPE for detecting conditions that preclude participation in sports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/5,52\">",
"     5,52",
"    </a>",
"    ]. Personal and family history and review of systems detect approximately 80 percent of conditions that restrict participation or require further evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/3,53\">",
"     3,53",
"    </a>",
"    ]. Parents should review the family history with the athlete if they will not be present for the examination.",
"   </p>",
"   <p>",
"    The history should include a general medical history, injury history, and a cardiovascular history, including pertinent family history. Particular attention should be paid to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Past medical history, including conditions currently being treated",
"     </li>",
"     <li>",
"      Prior surgery and sequelae",
"     </li>",
"     <li>",
"      Loss of function in one of any paired organs (eg, eye, testis, kidney)",
"     </li>",
"     <li>",
"      History of heat-related illness",
"     </li>",
"     <li>",
"      Current medications, supplements, or herbal therapy",
"     </li>",
"     <li>",
"      Immunization history",
"     </li>",
"     <li>",
"      Menstrual history in female athletes",
"     </li>",
"     <li>",
"      A history of rapid increase or decrease in body weight and the athlete's perception of his or her current body weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Injury history",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the PPE examiner must pay attention to the injury history because injuries are common and, if not adequately rehabilitated, can predispose the athlete to further injury. The examiner should inquire about:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Past injuries, including loss of time from participation and current sequelae of those injuries (eg, paresthesias from spinal injury).",
"     </li>",
"     <li>",
"      A loss of consciousness or amnesia following a head injury. Repeated concussions can be criteria for exclusion from contact sports. Almost 5 percent of high school athletes reported a previous history of concussion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link\">",
"       \"Concussion and mild traumatic brain injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Previous exclusion from sports for any reason.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cardiovascular history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular conditions that predispose athletes to sudden death are rare and difficult to detect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Young athletes'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Conditions that limit participation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority of individuals with hypertrophic cardiomyopathy are not symptomatic. However, they may have dyspnea or chest pain with exercise, syncope, palpitations, or postural lightheadedness. In addition, the family history may be positive in this autosomal dominantly inherited disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link&amp;anchor=H274524#H274524\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children and adolescents with coronary artery anomalies also are usually asymptomatic, although they too may have complaints of angina or syncope. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=see_link\">",
"     \"Congenital and pediatric coronary artery abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Questions of importance in the cardiovascular history include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31318?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening to prevent sudden cardiac death in athletes\", section on 'Major society guidelines'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Past history of hypertension, cardiac murmur, high cholesterol, Kawasaki disease, heart infection.",
"     </li>",
"     <li>",
"      Past history of syncope, near syncope, dizziness, angina, or palpitations during exercise. The athlete should be asked specifically if he or she has passed out; has nearly passed out; has felt lightheaded; or has had chest pain, an irregular heartbeat, or excessive, unexpected, or exceptional, unexplained shortness of breath or fatigue during or after exercise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1,40,41\">",
"       1,40,41",
"      </a>",
"      ]. Feeling lightheaded or having a near-syncopal or syncopal event is significant if it is judged to be not neurocardiogenic (vasovagal) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/41,54\">",
"       41,54",
"      </a>",
"      ]. True anginal pain, characterized by substernal, deep, pressure-like pain that radiates and is associated with dyspnea and causes the athlete to stop activity, is unusual in adolescents. The presence of any of the above symptoms that cannot be explained (eg, by vasovagal presyncope) requires exclusion from participation in competitive sports pending cardiac evaluation, and the patient should also be counseled to avoid strenuous exercise until that evaluation is complete. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Noninvasive cardiovascular evaluation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A history of chest pain. Although chest pain is a common complaint in children and adolescents, characteristics that suggest an organic etiology and require further evaluation are onset less than 48 hours, associated fever or interrupted sleep, and abnormal findings on physical examination. This is in addition to warning signs of cardiac disease such as angina, palpitations, and syncope during exercise, discussed under cardiac screening. &nbsp;",
"     </li>",
"     <li>",
"      A history of unexplained seizure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A history of cardiac testing (eg, electrocardiogram, echocardiogram).",
"     </li>",
"     <li>",
"      Feeling tired or short of breath more quickly than peers during exercise that is not due to poor conditioning or exercise-induced bronchospasm.",
"     </li>",
"     <li>",
"      A family history of death from heart problems, unexpected or unexplained sudden death before age 50 years (including drowning, unexplained car accident, or sudden infant death syndrome).",
"     </li>",
"     <li>",
"      A family history of hypertrophic cardiomyopathy, Marfan syndrome, arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, short QT syndrome, Brugada syndrome, or catecholaminergic polymorphic ventricular tachycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A family history of a heart problem, pacemaker, or implanted defibrillator.",
"     </li>",
"     <li>",
"      A family history of unexplained fainting, unexplained seizures, or near drowning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Musculoskeletal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening musculoskeletal evaluation is described below. Athletes with a history of injury or abnormalities identified on screening examination require the complete examination of the joint or region in question. One study of the \"two-minute\" orthopedic examination of 259 athletes with 120 significant injuries found the sensitivity, specificity, positive predictive value, and negative predictive value of the screening examination to detect injury to be 51 percent, 97 percent, 41 percent, and 98 percent, respectively, when the examiners were unaware of the athletes' injury history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/55\">",
"     55",
"    </a>",
"    ]. However, the ability of the screening musculoskeletal examination, including tests for flexibility and strength, to predict future injuries has never been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Complete examination of the high-risk areas (shoulder, knee, and ankle) may increase the sensitivity of the examination. However, this has never been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An accurate diagnosis must be established before a recommendation to participate is made. The diagnosis of a \"sprained knee\" or shoulder \"bursitis\", for example, is not adequate. If the PPE is being conducted in a setting that does not allow a thorough evaluation, the athlete can return for further evaluation but should not be cleared to participate until the diagnosis is made. Consultation with a sports medicine specialist may be indicated to establish a definitive diagnosis, to determine the need for radiologic imaging, or to make recommendations for sports participation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     General inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination requires the athlete to wear clothing that permits inspection of the shoulders and extremities. The screening orthopedic examination begins with inspection of the adolescent standing with arms at the sides, facing the examiner. The observer is looking for asymmetry. Specifically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A tilt of the head to one side can indicate a primary cervical spine injury, primary or secondary trapezius strain, or other cervical muscle spasm. Ask the athlete if any maneuver hurts or, if the parent or coach is in the room, ask him or her if this is a change in the athlete's posture. If pain occurs with movement or restriction of movement, the athlete is not permitted to participate in contact sports until further evaluation. Participation in noncontact sports is appropriate if participation does not exacerbate pain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18842?source=see_link\">",
"       \"Evaluation of neck stiffness in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prominence of one acromioclavicular joint usually indicates a previous acromioclavicular joint sprain (shoulder separation). The athlete can participate in all sports if no tenderness to palpation at the joint is present and if the range of motion and strength of the shoulder are normal. The acromioclavicular joint should be padded during participation so that the force, such as in direct contact of the shoulder with another athlete, can be distributed anterior and posterior to the acromioclavicular joint.",
"     </li>",
"     <li>",
"      Asymmetric shoulder heights indicate trapezius strain or spasm secondary to neck or shoulder injury, paraspinous strain, primary spine injury causing secondary paraspinous muscle spasm, limb length discrepancy, or scoliosis. The athlete is not permitted to participate in contact sports until the etiology is established and appropriate treatment, if necessary, is completed.",
"     </li>",
"     <li>",
"      Asymmetric iliac crest heights indicate scoliosis, leg length discrepancy, asymmetric pelvic rotation, or lumbar paraspinous muscle spasm.",
"     </li>",
"     <li>",
"      Atrophy of the vastus medialis obliquus, demonstrated by asking the athlete to contract his or her quadriceps muscles, is characteristic of any leg injury that leads the athlete to avoid normal use.",
"     </li>",
"     <li>",
"      A prominent, tender tibial tuberosity indicates Osgood-Schlatter disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12392?source=see_link\">",
"       \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Swelling of any extremity may be secondary to trauma or other inflammatory processes, and the etiology should be established before the athlete is cleared.",
"     </li>",
"     <li>",
"      Long limbs relative to the trunk, arachnodactyly, and pectus deformity of the chest may be present in Marfan syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neck examination is especially important in players with a previous history of neck injury, limited neck motion, or brachial plexopathy (stinging or burning in any dermatome of the brachial plexus distribution, referred to as \"stingers\" or \"burners\"). Ask the athlete to look at the floor (cervical flexion), the ceiling (cervical extension), over left and right shoulders (left and right rotation), and put the right ear on the right shoulder and the left ear on the left shoulder (right and left lateral flexion). Any athlete with limitation of range of motion, weakness, or pain with neck examination is excluded from contact sports until further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23689?source=see_link\">",
"     \"Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/49/11033?source=see_link\">",
"     \"Overview of musculoskeletal neck injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Shoulder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the athlete to raise the arms from the side and touch hands above the head, keeping elbows extended (full abduction). Asymmetric elevation of the shoulder before 90 degrees of abduction or inability to fully abduct the arms to 180 degrees could be caused by shoulder weakness or instability.",
"   </p>",
"   <p>",
"    Ask the athlete to hold the arms in front of the body while the examiner presses down on the hands (resisted forward flexion) and then repeat this procedure at 90 degrees of abduction. Weakness, atrophy, or fasciculations of anterior and middle deltoid muscles and pain or weakness with these maneuvers may indicate neurologic, skeletal, or muscular injury.",
"   </p>",
"   <p>",
"    Ask the athlete to put the hands behind the neck and bring the elbows back as far as possible (abduction and external rotation of the shoulder). Inability to perform this maneuver fully or apprehension about performing it, coupled with a history of the shoulder \"slipping out\" or \"going dead\", suggests previous shoulder subluxation or dislocation that has not been adequately rehabilitated or may need surgical correction.",
"   </p>",
"   <p>",
"    Athletes with limitation of motion in any of the above maneuvers should be further evaluated before they are cleared for participation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the athlete to extend and flex the elbows with arms to the side (90 degrees abduction). Then, with the elbows flexed at 90 degrees and the hands pointing forward, ask the athlete to pronate and supinate. Asymmetry or loss of motion in any of these maneuvers suggests previous injury. Further evaluation is necessary before the athlete can be cleared for participation, especially in throwing sports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the athlete to spread the fingers and then to make a fist. Look for decreased finger flexion, swollen joints, or finger deformities as residuals of previous injuries. The need for further evaluation of hand injuries and recommendations for sports participation are based upon the severity of the injury and the sport the athlete wishes to play.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Back",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspect the back from behind and in front of the athlete looking for manifestations of scoliosis. Idiopathic scoliosis rarely is a contraindication for sports participation unless the angle of curvature is severe (eg, &gt;40 degrees). If the spine is painful by history or tender to palpation, the diagnosis of idiopathic scoliosis should be reconsidered; the definitive diagnosis should be established before clearance for sports participation is provided. If the athlete reports lumbar pain and there is pain in the midline in the lumbar region with lumbar extension, lumbar spondylolysis should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=see_link&amp;anchor=H7#H7\">",
"     \"Back pain in children and adolescents: Overview of causes\", section on 'Spondylolysis and spondylolisthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Knee and hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the athlete to squat by placing the buttocks on the heels and then, remaining in this position, to take four steps forward (\"duck walk\"), turn around, and take four steps back to the starting position.",
"   </p>",
"   <p>",
"    Prominent, tender tibial tuberosities, diagnostic of Osgood-Schlatter disease and common in young adolescents, may cause pain when the athlete tries to squat in full knee flexion. Athletes with Osgood-Schlatter should not be disqualified from play but should participate in a rehabilitative program that includes stretching of the quadriceps and hamstring muscles, strengthening of the quadriceps muscles, and wearing a protective pad over the tibial tuberosity. The athlete should miss little if any sports participation with this treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12392?source=see_link\">",
"     \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inability to do the \"duck walk\" maneuver should prompt a thorough knee and hip examination and exclusion from painful activities until a definitive diagnosis and rehabilitation plan are established. Most diagnoses of knee problems can be made on the basis of history and physical examination. Consultation with a sports medicine specialist may be necessary to determine the need for additional studies, such as radiographs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging, especially if the knee and hip condition does not improve with rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Ankle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the athlete to hop as high as he or she can five times on each foot. The inability to hop five times on an ankle without pain or instability indicates an undiagnosed or unrehabilitated ankle or foot injury. The injury should be evaluated and fully rehabilitated before full participation is allowed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cardiac examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular physical examination should include, but not be limited to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1,40,41\">",
"     1,40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of blood pressure and resting pulse",
"     </li>",
"     <li>",
"      Precordial auscultation in the supine and standing positions",
"     </li>",
"     <li>",
"      Assessment of femoral pulses in the setting of hypertension or if concerned about coarctation of the aorta",
"     </li>",
"     <li>",
"      Location of the point of maximal impulse (PMI)",
"     </li>",
"     <li>",
"      Recognition of the physical stigmata of Marfan syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure should be measured in the right arm with the athlete sitting and with the proper size cuff. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link&amp;anchor=H11#H11\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Measurement of blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Training bradycardia, resting pulse as low as 25 beats per minute, can be present in highly trained aerobic athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/7\">",
"     7",
"    </a>",
"    ]. Elite adolescent athletes rarely attain a resting pulse lower than 40 to 50 beats per minute. Asymptomatic adolescent athletes with heart rates in this range can participate without further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PPE examiner should listen for murmurs and to the rate and rhythm of the heart.",
"   </p>",
"   <p>",
"    Innocent or functional cardiac murmurs typically are less than",
"    <span class=\"nowrap\">",
"     IV/VI",
"    </span>",
"    in intensity, systolic murmurs that decrease with position change from supine to standing, have no diastolic component, and are associated with a normal physiologic split of the second heart sound.",
"   </p>",
"   <p>",
"    The murmur of hypertrophic cardiomyopathy, if one is present, may sound like a normal murmur except that it increases in intensity with standing and during the Valsalva maneuver and decreases in intensity with squatting. The athlete with suspected hypertrophic cardiomyopathy is excluded from all participation until the full cardiology evaluation is complete. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Hypertrophic cardiomyopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link&amp;anchor=H274524#H274524\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The auscultatory findings of aortic stenosis include a soft and narrowly split or single S2 and a systolic \"ejection\" murmur typically heard best at the base of the heart. The murmur has a harsh quality (",
"    <a class=\"graphic graphic_movie graphicRef72877 \" href=\"mobipreview.htm?43/6/44128\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef77091 \" href=\"mobipreview.htm?39/8/40065\">",
"     movie 2",
"    </a>",
"    ) and is transmitted well and equally to the carotid arteries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link\">",
"     \"Valvar aortic stenosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A midsystolic click, with or without a late systolic murmur, is the auscultatory hallmark of mitral valve prolapse (",
"    <a class=\"graphic graphic_movie graphicRef57858 \" href=\"mobipreview.htm?7/55/8051\">",
"     movie 3",
"    </a>",
"    ). Echocardiography to evaluate mitral insufficiency is indicated only if a murmur is present. Mitral valve prolapse generally is a benign, asymptomatic condition. However, it is a minor criterion for the diagnosis of Marfan syndrome and can be associated with mitral insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13705?source=see_link\">",
"     \"Definition and diagnosis of mitral valve prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Targeted PE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remainder of the physical examination aids in the detection of other medical conditions that may restrict, affect, or worsen with participation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Anthropometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Height and weight are measured and used to estimate ideal body weight (IBW) or to calculate body mass index (BMI), which equals&nbsp;the weight (in kg) divided by&nbsp;the height ([in meters] squared) (",
"    <a class=\"graphic graphic_figure graphicRef65305 \" href=\"mobipreview.htm?12/3/12351\">",
"     figure 2",
"    </a>",
"    ). Obesity in children and adolescents is defined as BMI &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age and gender (",
"    <a class=\"graphic graphic_figure graphicRef60784 graphicRef68478 \" href=\"mobipreview.htm?10/0/10247\">",
"     figure 3A-B",
"    </a>",
"    ); in adults, it is defined as BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    BMI is the preferred measure of adiposity for routine clinical and public health purposes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. If the athlete is obese, the author asks if he or she would like to lose weight, gain weight, or stay at the same weight. In football lineman, for example, obesity is common, and there may not be an interest in losing weight. If the athlete is interested in losing weight, the author develops a plan to change one or two dietary practices (eg, making sure he or she eats breakfast and limiting juice and regular soda intake). Obesity should be diagnosed and mentioned to the athlete, parents, and coach as a risk factor for heat illness but is not a reason for exclusion from sports. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The author prefers to use percent IBW for discussing degree of malnutrition (&lt;85 percent IBW) and treatment plans with patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H25#H25\">",
"     \"Normal growth patterns in infants and prepubertal children\", section on 'Ideal body weight'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low body weight, especially in wrestlers and female athletes with menstrual or eating disorders, must be noted. Further evaluation may be indicated and restriction from full participation warranted, depending upon the degree of malnutrition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimating body composition using anthropometric (eg, skinfold) measurements is indicated in wrestling because prediction equations for minimum wrestling weight have been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The American College of Sports Medicine recommends that boys younger than 16 years with body fat below 7 percent, boys older than 16 years with body fat below 5 percent, and girls with body fat less than 12 percent have medical clearance before competition in wrestling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Although some use skinfold measurements to monitor athletes who are on weight gain or weight loss programs, the author monitors body weight as a function of estimated IBW, along with pulse, blood pressure, and body temperature, looking for evidence of a hypometabolic state manifest as bradycardia, hypothermia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension, often seen in patients with eating disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=see_link\">",
"     \"Measurement of growth in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes with best corrected visual acuity less than",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    in one or both eyes should be referred for further evaluation but are not excluded from participation. They should wear protective eyewear during sports participation since injury to the better eye could leave them with significant disability. Among 148 eye injuries reported in the 1995-1997 National Athletic Trainers&rsquo; Association High School Injury Surveillance Study, 28 percent occurred while playing basketball, 20 percent during wrestling, 15 percent in",
"    <span class=\"nowrap\">",
"     baseball/softball,",
"    </span>",
"    15 percent in football, and 14 percent in soccer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anisocoria is theoretically important to note prior to a closed head injury but has had little practical application in the author's experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes who have skin infections that are contagious (eg, varicella, impetigo, tinea corporis, scabies, molluscum contagiosum, and herpes simplex virus) require disqualification from sports that involve close physical contact or shared equipment such as gymnastics mats. (See appropriate topic reviews). Participation can resume when the athlete's lesions can be adequately covered or when they are no longer infectious. The Centers for Disease Control and Prevention provide guidance about preventing methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    infections in athletic facilities (",
"    <a class=\"external\" href=\"file://www.cdc.gov/mrsa/prevent/athletic.html\">",
"     www.cdc.gov/mrsa/prevent/athletic.html",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenopathy alone is not a criterion for disqualification from sports but should prompt further evaluation because it may be the manifestation of an infectious or malignant process that might preclude sports participation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24857?source=see_link\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Respiratory system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wheezing that is noted on auscultation of the lungs, especially after exercise, in an otherwise asymptomatic athlete, is suggestive of asthma or exercise-induced bronchoconstriction. The athlete also may have a history of exercise-related cough or chest tightness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Production of chest pain by applying pressure over the sternum while the athlete is in the supine position is characteristic of costochondritis, a common condition in adolescents that need not exclude them from participation but should be distinguished from cardiovascular causes of chest pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=see_link\">",
"     \"Approach to chest pain in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organomegaly is a disqualifying condition for contact sports. A list of sports according to level of contact is provided in the full text of reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Genitourinary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 guidelines suggest that the athlete be asked if he or she would prefer to have a chaperone present for the genitourinary examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1\">",
"     1",
"    </a>",
"    ]. This suggestion is not based upon medical evidence, but to ensure that the athlete and examiner are comfortable with the circumstances of the examination.",
"   </p>",
"   <p>",
"    Boys with a single testicle (eg, undescended testicle, orchiectomy) can participate in contact sports if they wear a protective cup. Among nearly 3 million male athlete exposures (one athlete participating in one game or practice) in the National Athletic Trainers&rsquo; Association High School Injury Surveillance Study (1995 to 1997), there were only 17 testicular injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/65\">",
"     65",
"    </a>",
"    ]. Of these, 12 occurred while playing football, three soccer, and one wrestling. Further urologic evaluation is indicated to determine the proper etiology and management of the undescended testis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17098?source=see_link\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Having a single kidney has been considered to be a disqualifying condition for contact sports. However, review of the literature and data from the National Pediatric Trauma Registry from 1995 to 2001 suggests that activities other than contact sports, such as cycling, may be more risky for individuals with a single kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Between 1995 and 2001, there were 813 renal injuries in children (mean age 10.3 years), 28 of which resulted in nephrectomy; only seven of these occurred during sports participation or recreational activities: three during equestrian activities, two in sledding, one in skiing, and one in rollerblading; none occurred during contact sports. In addition, among more than 4.4 million male and female athlete exposures in the 1995-1997 National Athletic Trainers&rsquo; Association High School Injury Surveillance Study, there were only 18 kidney injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/65\">",
"     65",
"    </a>",
"    ]. Of these, 12 occurred while playing football, three soccer, two basketball, and one baseball. None of the injuries required surgery. In light of these studies, the author recommends that youth with a single kidney be allowed to participate in contact sports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tanner stage assessment of sexual maturity can be useful in helping athletes to choose a sport in which he or she is likely to succeed. Athletes whose small size or maturational immaturity put them at a disadvantage in sports where size and strength are critical to performance can be encouraged to participate in other sports until their maturation ensues. No data support the recommendation that teens below the second or third stage of pubertal development avoid contact sports, or that those playing contact sports be segregated according to early, middle, or late puberty to reduce the risk of injury. In fact, injury rates during sports participation increase with increasing age and pubertal maturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory testing is not recommended as part of the preparticipation physical examination in the absence of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/1,70\">",
"     1,70",
"    </a>",
"    ]. State regulations that require blood and urine testing as part of the preparticipation physical evaluation (PPE) are antiquated. Most of the positive screening tests are false positives because the conditions being tested for have a low prevalence in the young, athletic population. As an example, urine testing by dipstick for protein, blood, and glucose was performed as part of the preparticipation sports assessment of 701 students [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/3\">",
"     3",
"    </a>",
"    ]. Proteinuria was detected in 40 students, and glucosuria in one. Follow-up testing with first-voided morning urine specimens and glucose tolerance test were normal in all students.",
"   </p>",
"   <p>",
"    Measurement of hemoglobin is not recommended for athletes who receive regular health maintenance care and have no symptoms of anemia. However, it may be indicated for teenagers who do not have ongoing medical care. In addition, some experts advocate screening menstruating female athletes for iron deficiency, especially if they run long-distance events. Finally, pseudoanemia can be misdiagnosed as anemia in highly trained aerobic athletes who have reduced hematocrit but normal or increased oxygen-carrying capacity because of intravascular volume expansion from chronic aerobic training. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4329?source=see_link&amp;anchor=H22449346#H22449346\">",
"     \"Iron requirements and iron deficiency in adolescents\", section on 'Whom to screen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     STRENGTH EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isokinetic or isotonic equipment to assess for muscle weakness, especially quadriceps and hamstring weakness or asymmetry, is used in some settings. This testing may be reasonable if the equipment is available to the athletes at no extra cost and if it is used to evaluate the recovery of athletes with previous injuries.",
"   </p>",
"   <p>",
"    Athletes with previous injuries and with identified asymmetry in strength and flexibility on specific directed testing of the lower extremities may have an increased risk of injury to either extremity during the season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the etiology of that increased risk, in terms of physiologic factors, has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/56\">",
"     56",
"    </a>",
"    ]. The rate of injury can be reduced with rehabilitation of previous deficits. However, the utility for screening all athletes with strength-testing equipment compared with the history and physical examination has not been established. The author recommends using history and physical examination to screen for residua of previous injuries that would prevent sports participation. Again, however, the screening preparticipation physical evaluation (PPE), as described, has not been shown to predict future injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     NONINVASIVE CARDIOVASCULAR EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive cardiovascular evaluation of athletes before participation is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31318?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening to prevent sudden cardiac death in athletes\", section on 'Comparison of guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mandated preseason examinations in Italy have included a history, physical examination, and 12-lead electrocardiogram (EKG) since 1982. Since the implementation of this policy, the incidence of sudden cardiac deaths in 12- to 35-year-old athletes in one region of Italy, Veneto, has decreased secondary to the decrease in deaths due to arrhythmogenic right ventricular hypertrophy (ARVC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/75\">",
"     75",
"    </a>",
"    ]. The number of deaths due to other causes, including hypertrophic cardiomyopathy, did not change. In Veneto, ARVC and premature atherosclerotic coronary artery disease predominate as causes of unexpected, sudden cardiac deaths in young people [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/76\">",
"     76",
"    </a>",
"    ]. In other countries, and in different age groups, the predominant causes of sudden unexpected death may differ. As an example, in a retrospective 30-year (1980-2009) review of cardiovascular-related out-of-hospital cardiac arrest in individuals &lt;35 years of age, none of the sudden unexpected deaths in individuals &lt;25 years of age were due to coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the Italian experience, mandated preparticipation EKG and exercise testing in Israel had no effect on the incidence of sudden cardiac death in athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, cardiac ultrasound, electrocardiography, and graded exercise testing are not recommended as routine screening methods for detection of cardiovascular disease in large groups of athletes as part of the preparticipation physical evaluation (PPE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/41\">",
"     41",
"    </a>",
"    ]. This recommendation is based upon practical and cost-efficiency considerations, given the low prevalence of the cardiovascular lesions that cause sudden death (5 per 100,000 young athletes), the low rate of sudden death in the athletic community (between 10 to 25 sports-related sudden deaths per year in the United States), the large number of athletes who would need to be screened (200,000) to detect one who would actually die, difficulty in accurate interpretation of EKGs (even among pediatric cardiologists), and the significant rate of false-positive findings that would require more extensive evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/40,52,79-83\">",
"     40,52,79-83",
"    </a>",
"    ]. In addition, the use of echocardiography as a screening tool would require consistency of interpretation. The potential for a large number of false positive readings, requiring more extensive testing, unnecessary anxiety on the part of the patient and family, and time away from sports, particularly for athletes without access to a pediatric cardiologist, is another risk to widespread use of the echocardiogram as a routine screen. The author does not support the use of echocardiograms or screening EKGs in the context of the PPE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39945?source=see_link&amp;anchor=H871783392#H871783392\">",
"     \"Sudden cardiac arrest and death in children\", section on 'Method of screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The athlete should have further evaluation if cardiovascular abnormalities are identified or suspected on the basis of the history and physical examination. The cardiovascular evaluation should include an electrocardiogram, Holter or event capture monitor, echocardiogram, and a maximum stress test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/84\">",
"     84",
"    </a>",
"    ]. If the evaluation is otherwise normal and the athlete has no symptoms during Holter or event monitoring, he or she should return to exercise with the monitor, to see if an event can be captured during exercise. Invasive electrophysiologic testing may be considered in athletes with syncope in whom no other cause is found. The tilt table test is too nonspecific to be recommended for all subjects with these complaints.",
"   </p>",
"   <p>",
"    Eligibility for play in athletes with confirmed cardiovascular abnormalities should be determined in concordance with the 36",
"    <sup>",
"     th",
"    </sup>",
"    Bethesda Conference panel guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     CONDITIONS DETECTED DURING PREPARTICIPATION EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few students are restricted from sports participation on the basis of the preparticipation evaluation. As described above, most of the conditions that affect sports participation are detected by the history. Musculoskeletal complaints, especially regarding the knee, are most common, followed by cardiovascular and neurologic complaints (eg, headache and dizziness after head trauma). In several large studies, 5.6 to 8 percent are referred for further evaluation and 0.3 to 1.3 percent are restricted from participation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/3,5,50\">",
"     3,5,50",
"    </a>",
"    ]. Conditions that restricted athletic participation in these studies included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Knee instability",
"     </li>",
"     <li>",
"      Scoliosis*",
"     </li>",
"     <li>",
"      Femur fracture",
"     </li>",
"     <li>",
"      Elbow dislocation",
"     </li>",
"     <li>",
"      Ventricular arrhythmia",
"     </li>",
"     <li>",
"      Congenital heart disease",
"     </li>",
"     <li>",
"      Recurrent concussion",
"     </li>",
"     <li>",
"      Abdominal mass",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    *Of note, adolescent idiopathic scoliosis that is not painful or causes no functional limitations is not a reason for limitation from sports. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR SPORTS PARTICIPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the examination, the athlete should be given full clearance for participation, clearance to participate with limitations, or exclusion from participation pending further evaluation. Guidelines for sports participation for children with various medical conditions are provided in the full text of reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6\">",
"     6",
"    </a>",
"    ]. Using these guidelines, the examining clinician can advise the athlete regarding safe sports in which to participate, with the understanding that for many conditions, the decision is made on a case-by-case basis and there are not data to determine the risk of injury for every condition.",
"   </p>",
"   <p>",
"    Restrictions to participation should be discussed in detail with the athlete, the athlete's parents, and the coach to minimize the likelihood of misinterpretation. The risks of continued participation must be discussed in the context of the medical problem and the athlete's chosen sport. The plan for further evaluation and treatment also should be discussed.",
"   </p>",
"   <p>",
"    Similarly, limitations to participation must be discussed in detail with the athlete, parents, and coach. Athletes with Osgood-Schlatter disease, for example, can limit pain with sports participation (if they desire to do so) if they wear protective padding and are involved in a rehabilitation program. Children and adolescents with diabetes mellitus or exercise-induced bronchoconstriction can participate with proper pre-exercise medication.",
"   </p>",
"   <p>",
"    Sports can be classified according to the static and dynamic cardiovascular load (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"mobipreview.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    ) or by the level of contact with other athletes. A list of sports according to level of contact is provided in the full text of reference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6\">",
"     6",
"    </a>",
"    ]. These classifications help the clinician in advising athletes regarding appropriate sports in which to participate. The distinction between recreational and competitive sports, in the context of patients with the genetic cardiovascular diseases Marfan syndrome, long QT syndrome, arrhythmogenic right ventricular cardiomyopathy, and hypertrophic cardiomyopathy, was drawn, and suggestions were made for physical activity in these conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above recommendations are guidelines that should be individualized for each athlete. The clinician's recommendation to play after diagnosis of a medical or musculoskeletal problem should be made in the context of the age and maturity of the patient, the severity of the injury, the sport activity, the importance of the upcoming event to the athlete (eg, a state championship game versus a preseason scrimmage), and the sequelae if the athlete is injured further. The health of the athlete is the overriding priority.",
"   </p>",
"   <p>",
"    Athletes have had legal recourse to seek the right to participate in a sport against medical advice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the courts have upheld clinicians&rsquo; decisions to exclude athletes based upon recommendations in current expert guidelines such as the 36",
"    <sup>",
"     th",
"    </sup>",
"    Bethesda Guidelines (Knapp versus Northwestern, 1996) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/87\">",
"     87",
"    </a>",
"    ]. In these circumstances, the clinician should document in the medical record the recommendation to avoid participation and that this recommendation was discussed with the athlete and the athlete's parents. Some clinicians suggest requesting that the parents and athlete sign a document describing these discussions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of the preparticipation physical evaluation (PPE) include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of the preparticipation sports examination'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      To identify medical problems with risks of life-threatening complications during participation",
"     </li>",
"     <li>",
"      To identify conditions that require a treatment plan before or during participation",
"     </li>",
"     <li>",
"      To identify and rehabilitate old musculoskeletal injuries",
"     </li>",
"     <li>",
"      To identify and treat conditions that interfere with performance",
"     </li>",
"     <li>",
"      To remove unnecessary restrictions on participation",
"     </li>",
"     <li>",
"      To advise athletes regarding appropriate sports in which to participate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PPE includes a targeted medical and family history and a targeted physical examination, with particular emphasis on the musculoskeletal and cardiovascular systems. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Components of the evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The medical history is the most sensitive and specific component of the PPE for detecting conditions that preclude participation in sports. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Medical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the injury history include past injuries, including loss of time from participation and current sequelae of those injuries; loss of consciousness or amnesia following a head injury; and previous exclusion from sports for any reason. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Injury history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Questions of particular importance in the cardiovascular history include past history of hypertension or cardiac murmur; past history of syncope, near syncope, angina, or palpitations during exercise, or dizziness associated with any of these; a history of chest pain; and family history of cardiovascular disease (especially sudden cardiac death at younger than 50 years of age), hypertrophic cardiomyopathy, dilated cardiomyopathy, long QT syndrome, Marfan syndrome, or clinically important arrhythmias. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cardiovascular history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardiovascular physical examination should include, but not be limited to, measurement of blood pressure and resting pulse, precordial auscultation in the supine and standing positions, simultaneous assessment of the radial and femoral pulses, location of the point of maximal impulse, and recognition of the physical stigmata of Marfan syndrome. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Cardiac examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine laboratory testing is not recommended as part of the preparticipation physical examination in the absence of symptoms. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, cardiac ultrasound, electrocardiography, and graded exercise testing are not recommended as routine screening methods for detection of cardiovascular disease in large groups of athletes as part of the PPE. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Noninvasive cardiovascular evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the examination, the athlete should be given full clearance for participation, clearance to participate with limitations, or exclusion from participation pending further evaluation. Guidelines for sports participation for children with various medical conditions are provided in the full text of reference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H42\">",
"       'Recommendations for sports participation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Academy of Family Physicians, American Academy of Pediatrics, American College of Sports Medicine. Preparticipation Physical Evaluation, 4th ed, Bernhardt D, Roberts W (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2010.",
"    </li>",
"    <li>",
"     American Medical Association. Guidelines for Adolescent Preventive Services (GAPS)., Elster A (Ed), Williams &amp; Wilkins, Baltimore, MD 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/3\">",
"      Goldberg B, Saraniti A, Witman P, et al. Pre-participation sports assessment--an objective evaluation. Pediatrics 1980; 66:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/4\">",
"      Krowchuk DP, Krowchuk HV, Hunter DM, et al. Parents' knowledge of the purposes and content of preparticipation physical examinations. Arch Pediatr Adolesc Med 1995; 149:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/5\">",
"      Risser WL, Hoffman HM, Bellah GG Jr, Green LW. A cost-benefit analysis of preparticipation sports examinations of adolescent athletes. J Sch Health 1985; 55:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/6\">",
"      Rice SG, American Academy of Pediatrics Council on Sports Medicine and Fitness. Medical conditions affecting sports participation. Pediatrics 2008; 121:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/7\">",
"      26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. January 6-7, 1994. J Am Coll Cardiol 1994; 24:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/8\">",
"      Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/9\">",
"      Van Camp SP, Bloor CM, Mueller FO, et al. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc 1995; 27:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/10\">",
"      Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/11\">",
"      Maron BJ, Bodison SA, Wesley YE, et al. Results of screening a large group of intercollegiate competitive athletes for cardiovascular disease. J Am Coll Cardiol 1987; 10:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/12\">",
"      Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/13\">",
"      Baggish AL, Hutter AM Jr, Wang F, et al. Cardiovascular screening in college athletes with and without electrocardiography: A cross-sectional study. Ann Intern Med 2010; 152:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/14\">",
"      Fuller CM, McNulty CM, Spring DA, et al. Prospective screening of 5,615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc 1997; 29:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/15\">",
"      Wilson MG, Basavarajaiah S, Whyte GP, et al. Efficacy of personal symptom and family history questionnaires when screening for inherited cardiac pathologies: the role of electrocardiography. Br J Sports Med 2008; 42:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/16\">",
"      McCambridge TM, Benjamin HJ, Brenner JS, et al. Athletic participation by children and adolescents who have systemic hypertension. Pediatrics 2010; 125:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/17\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/18\">",
"      Rupp NT, Guill MF, Brudno DS. Unrecognized exercise-induced bronchospasm in adolescent athletes. Am J Dis Child 1992; 146:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/19\">",
"      Hallstrand TS, Curtis JR, Koepsell TD, et al. Effectiveness of screening examinations to detect unrecognized exercise-induced bronchoconstriction. J Pediatr 2002; 141:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/20\">",
"      Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/21\">",
"      American Academy of Pediatrics. Committee on Adolescence. Identifying and treating eating disorders. Pediatrics 2003; 111:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/22\">",
"      Hergenroeder AC, Brown B, Klish WJ. Anthropometric measurements and estimating body composition in ballet dancers. Med Sci Sports Exerc 1993; 25:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/23\">",
"      Climatic heat stress and the exercising child and adolescent. American Academy of Pediatrics. Committee on Sports Medicine and Fitness. Pediatrics 2000; 106:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/24\">",
"      Purcell L. What are the most appropriate return-to-play guidelines for concussed child athletes? Br J Sports Med 2009; 43 Suppl 1:i51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/25\">",
"      Halstead ME, Walter KD, Council on Sports Medicine and Fitness. American Academy of Pediatrics. Clinical report--sport-related concussion in children and adolescents. Pediatrics 2010; 126:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/26\">",
"      McCrory P, Johnston K, Meeuwisse W, et al. Summary and agreement statement of the 2nd International Conference on Concussion in Sport, Prague 2004. Clin J Sport Med 2005; 15:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/27\">",
"      Kirkwood MW, Yeates KO, Wilson PE. Pediatric sport-related concussion: a review of the clinical management of an oft-neglected population. Pediatrics 2006; 117:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Sports-related injuries among high school athletes--United States, 2005-06 school year. MMWR Morb Mortal Wkly Rep 2006; 55:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/29\">",
"      Brooks MA, Schiff MA, Rivara FP. Identifying previous sports injury among high school athletes. Clin Pediatr (Phila) 2009; 48:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/30\">",
"      Van Mechelen W, Twisk J, Molendijk A, et al. Subject-related risk factors for sports injuries: a 1-yr prospective study in young adults. Med Sci Sports Exerc 1996; 28:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/31\">",
"      DuRant RH, Pendergrast RA, Seymore C, et al. Findings from the preparticipation athletic examination and athletic injuries. Am J Dis Child 1992; 146:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/32\">",
"      Knapik JJ, Bauman CL, Jones BH, et al. Preseason strength and flexibility imbalances associated with athletic injuries in female collegiate athletes. Am J Sports Med 1991; 19:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/33\">",
"      Keller CS, Noyes FR, Buncher CR. The medical aspects of soccer injury epidemiology. Am J Sports Med 1987; 15:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/34\">",
"      Jones BH, Cowan DN, Tomlinson JP, et al. Epidemiology of injuries associated with physical training among young men in the army. Med Sci Sports Exerc 1993; 25:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/35\">",
"      Schmidt-Olsen S, J&oslash;rgensen U, Kaalund S, S&oslash;rensen J. Injuries among young soccer players. Am J Sports Med 1991; 19:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/36\">",
"      Ekstrand J, Gillquist J. The avoidability of soccer injuries. Int J Sports Med 1983; 4:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/37\">",
"      Abbott HG, Kress JB. Preconditioning in the prevention of knee injuries. Arch Phys Med Rehabil 1969; 50:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/38\">",
"      Ekstrand J, Gillquist J, Liljedahl SO. Prevention of soccer injuries. Supervision by doctor and physiotherapist. Am J Sports Med 1983; 11:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/39\">",
"      Bergman AB, Stamm SJ. The morbidity of cardiac nondisease in schoolchildren. N Engl J Med 1967; 276:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/40\">",
"      Maron BJ, Thompson PD, Puffer JC, et al. Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. Circulation 1996; 94:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/41\">",
"      Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2007; 115:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/42\">",
"      Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/43\">",
"      Rausch CM, Phillips GC. Adherence to guidelines for cardiovascular screening in current high school preparticipation evaluation forms. J Pediatr 2009; 155:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/44\">",
"      Black JL, Nader PR, Broyles SL, Nelson JA. A national survey on pediatric training and activities in school health. J Sch Health 1991; 61:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/45\">",
"      Anderson JM, Felsenthal G. Residency training in physical medicine and rehabilitation. I: Clinical and didactic experience. Arch Phys Med Rehabil 1990; 71:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/46\">",
"      Taras HL, Nader PR. Ten years of graduates evaluate a pediatric residency program. Am J Dis Child 1990; 144:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/47\">",
"      Stirling JM, Landry GL. Sports medicine training during pediatric residency. Arch Pediatr Adolesc Med 1996; 150:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/48\">",
"      Biro FM, Gillman MW, Parker RM, et al. Surveying graduates of combined internal medicine-pediatrics residency programs. Acad Med 1990; 65:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/49\">",
"      Bradford BJ, Lyons CW. Preparticipation sports assessment in western Pennsylvania. J Adolesc Health 1991; 12:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/50\">",
"      DuRant RH, Seymore C, Linder CW, Jay S. The preparticipation examination of athletes. Comparison of single and multiple examiners. Am J Dis Child 1985; 139:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/51\">",
"      Campbell RM, Berger S. Preventing pediatric sudden cardiac death: where do we start? Pediatrics 2006; 118:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/52\">",
"      Athletic preparticipation examinations for adolescents. Report of the Board of Trustees. Group on Science and Technology, American Medical Association. Arch Pediatr Adolesc Med 1994; 148:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/53\">",
"      Carek PJ, Mainous AG 3rd. A thorough yet efficient exam identifies most problems in school athletes. J Fam Pract 2003; 52:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/54\">",
"      Drezner JA, Fudge J, Harmon KG, et al. Warning symptoms and family history in children and young adults with sudden cardiac arrest. J Am Board Fam Med 2012; 25:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/55\">",
"      Gomez JE, Landry GL, Bernhardt DT. Critical evaluation of the 2-minute orthopedic screening examination. Am J Dis Child 1993; 147:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/56\">",
"      Garrick JG. Preparticipation orthopedic screening evaluation. Clin J Sport Med 2004; 14:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/57\">",
"      Meeuwisse WH, Fowler PJ. Frequency and predictability of sports injuries in intercollegiate athletes. Can J Sport Sci 1988; 13:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/58\">",
"      Ellis KJ, Abrams SA, Wong WW. Monitoring childhood obesity: assessment of the weight/height index. Am J Epidemiol 1999; 150:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/59\">",
"      Pietrobelli A, Faith MS, Allison DB, et al. Body mass index as a measure of adiposity among children and adolescents: a validation study. J Pediatr 1998; 132:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/60\">",
"      Maynard LM, Wisemandle W, Roche AF, et al. Childhood body composition in relation to body mass index. Pediatrics 2001; 107:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/61\">",
"      Oppliger RA, Harms RD, Herrmann DE, et al. The Wisconsin wrestling minimum weight project: a model for weight control among high school wrestlers. Med Sci Sports Exerc 1995; 27:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/62\">",
"      Oppliger RA, Case HS, Horswill CA, et al. American College of Sports Medicine position stand. Weight loss in wrestlers. Med Sci Sports Exerc 1996; 28:ix.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/63\">",
"      Thorland WG, Tipton CM, Lohman TG, et al. Midwest wrestling study: prediction of minimal weight for high school wrestlers. Med Sci Sports Exerc 1991; 23:1102.",
"     </a>",
"    </li>",
"    <li>",
"     McArdle WD, Katch FI, Katch VL. Exercise Physiology: Energy, Nutrition, and Human Performance, 3rd, Lea &amp; Febiger, Malvern, PA 1991. p.488.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/65\">",
"      Grinsell MM, Butz K, Gurka MJ, et al. Sport-related kidney injury among high school athletes. Pediatrics 2012; 130:e40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/66\">",
"      Johnson B, Christensen C, Dirusso S, et al. A need for reevaluation of sports participation recommendations for children with a solitary kidney. J Urol 2005; 174:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/67\">",
"      Grinsell MM, Showalter S, Gordon KA, Norwood VF. Single kidney and sports participation: perception versus reality. Pediatrics 2006; 118:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/68\">",
"      Backous DD, Friedl KE, Smith NJ, et al. Soccer injuries and their relation to physical maturity. Am J Dis Child 1988; 142:839.",
"     </a>",
"    </li>",
"    <li>",
"     Conference on Sports Injuries in Youth: Surveillance Strategies. National Institutes of Health, Bethesda, MD. Department of Health and Human Services, Public Health Service, NIH Publication No. 93-3444, November 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/70\">",
"      Vehaskari VM, Rapola J. Isolated proteinuria: analysis of a school-age population. J Pediatr 1982; 101:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/71\">",
"      Chaitman BR. An electrocardiogram should not be included in routine preparticipation screening of young athletes. Circulation 2007; 116:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/72\">",
"      Myerburg RJ, Vetter VL. Electrocardiograms should be included in preparticipation screening of athletes. Circulation 2007; 116:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/73\">",
"      Corrado D, Thiene G. Protagonist: routine screening of all athletes prior to participation in competitive sports should be mandatory to prevent sudden cardiac death. Heart Rhythm 2007; 4:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/74\">",
"      Viskin S. Antagonist: routine screening of all athletes prior to participation in competitive sports should be mandatory to prevent sudden cardiac death. Heart Rhythm 2007; 4:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/75\">",
"      Corrado D, Basso C, Pavei A, et al. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006; 296:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/76\">",
"      Corrado D, Basso C, Rizzoli G, et al. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003; 42:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/77\">",
"      Meyer L, Stubbs B, Fahrenbruch C, et al. Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: a 30-year review. Circulation 2012; 126:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/78\">",
"      Steinvil A, Chundadze T, Zeltser D, et al. Mandatory electrocardiographic screening of athletes to reduce their risk for sudden death proven fact or wishful thinking? J Am Coll Cardiol 2011; 57:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/79\">",
"      Van Camp SP. Sudden death. Clin Sports Med 1992; 11:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/80\">",
"      Epstein SE, Maron BJ. Sudden death and the competitive athlete: perspectives on preparticipation screening studies. J Am Coll Cardiol 1986; 7:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/81\">",
"      Maron BJ. National electrocardiography screening for competitive athletes: Feasible in the United States? Ann Intern Med 2010; 152:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/82\">",
"      Hill AC, Miyake CY, Grady S, Dubin AM. Accuracy of interpretation of preparticipation screening electrocardiograms. J Pediatr 2011; 159:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/83\">",
"      Schoenbaum M, Denchev P, Vitiello B, Kaltman JR. Economic evaluation of strategies to reduce sudden cardiac death in young athletes. Pediatrics 2012; 130:e380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/84\">",
"      Maron BJ, Douglas PS, Graham TP, et al. Task Force 1: preparticipation screening and diagnosis of cardiovascular disease in athletes. J Am Coll Cardiol 2005; 45:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/85\">",
"      Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol 2005; 45:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/86\">",
"      Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/13/36058/abstract/87\">",
"      Mitten MJ, Maron BJ, Zipes DP. Task Force 12: legal aspects of the 36th Bethesda Conference recommendations. J Am Coll Cardiol 2005; 45:1373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6472 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36058=[""].join("\n");
var outline_f35_13_36058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H43\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF THE PREPARTICIPATION SPORTS EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Conditions that limit participation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Conditions that require a treatment plan before or during exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Unnecessary restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GUIDELINES FOR PREPARTICIPATION SPORTS EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Consensus guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMPONENTS OF THE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Evaluation forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Injury history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cardiovascular history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Musculoskeletal examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - General inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Neck",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Shoulder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Elbow",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hands",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Back",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Knee and hip",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Ankle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cardiac examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Vital signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Auscultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Targeted PE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Anthropometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Eyes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Respiratory system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Abdomen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Genitourinary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Maturation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      STRENGTH EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      NONINVASIVE CARDIOVASCULAR EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      CONDITIONS DETECTED DURING PREPARTICIPATION EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      RECOMMENDATIONS FOR SPORTS PARTICIPATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6472|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/51/29489\" title=\"figure 1\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/3/12351\" title=\"figure 2\">",
"      Nomogram for BMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/23/38257\" title=\"figure 3A\">",
"      CDC BMI for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/2/40993\" title=\"figure 3B\">",
"      CDC BMI for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6472|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?43/6/44128\" title=\"movie 1\">",
"      Phonocardiogram of bicuspid AS at apex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?39/8/40065\" title=\"movie 2\">",
"      Phonocardiogram bicusid AS at 2nd R ICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?7/55/8051\" title=\"movie 3\">",
"      Mitral valve prolapse with patient standing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6472|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7894\" title=\"table 1\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/46/7910\" title=\"table 2\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/14/2285\" title=\"table 3\">",
"      Risk factors for heat illness in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=related_link\">",
"      Approach to chest pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=related_link\">",
"      Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12101?source=related_link\">",
"      Commotio cordis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13705?source=related_link\">",
"      Definition and diagnosis of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24857?source=related_link\">",
"      Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/25/18842?source=related_link\">",
"      Evaluation of neck stiffness in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19000?source=related_link\">",
"      Guidelines for adolescent preventive services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21878?source=related_link\">",
"      Heat illness (other than heat stroke) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10234?source=related_link\">",
"      Heat stroke in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12392?source=related_link\">",
"      Osgood-Schlatter disease (tibial tuberosity avulsion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23689?source=related_link\">",
"      Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/49/11033?source=related_link\">",
"      Overview of musculoskeletal neck injuries in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31318?source=related_link\">",
"      Screening to prevent sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/40/13960?source=related_link\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39945?source=related_link\">",
"      Sudden cardiac arrest and death in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_13_36059="Potass iodide radiation expos";
var content_f35_13_36059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended doses of potassium iodide after radiation exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\">",
"        Age of",
"patient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Predicted thyroid dose (cGy)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Daily dose of KI (mg)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;40 years",
"       </td>",
"       <td>",
"        &ge;",
"500",
"       </td>",
"       <td>",
"        130",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;18 through 40",
"       </td>",
"       <td>",
"        &ge; 10",
"       </td>",
"       <td>",
"        130",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnant or",
"lactating",
"       </td>",
"       <td>",
"        &ge; 5",
"       </td>",
"       <td>",
"        130",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;12 though 18 years",
"       </td>",
"       <td>",
"        &ge; 5",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;3 through 12 years",
"       </td>",
"       <td>",
"        &ge; 5",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;1 month through 3 years",
"       </td>",
"       <td>",
"        &ge; 5",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth through 1 month",
"       </td>",
"       <td>",
"        &ge; 5",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     KI: potassium iodide.",
"     <br>",
"      * Potassium iodide is available as 130 or 65 mg tablets, or as Lugol's solution. KI must be used within 4 to 6 hours of exposure to block uptake of radioactive iodine by the thyroid. If radioactive iodines are not part of the radiation exposure, KI is not needed. See text for details.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Based on FDA Guidance, 2001. Available at &lt;www.fda.gov/cder/guidance/4825fnl.htm&gt;.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36059=[""].join("\n");
var outline_f35_13_36059=null;
var title_f35_13_36060="PA catheter insertion sites";
var content_f35_13_36060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison among pulmonary artery (PA) catheter insertion sites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Insertion site",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Distance (cm) to:",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        RA",
"       </td>",
"       <td class=\"subtitle2\">",
"        RV",
"       </td>",
"       <td class=\"subtitle2\">",
"        PA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Internal jugular",
"       </td>",
"       <td rowspan=\"2\">",
"        15 to 20",
"       </td>",
"       <td rowspan=\"2\">",
"        30",
"       </td>",
"       <td rowspan=\"2\">",
"        40",
"       </td>",
"       <td>",
"        Easy to float, esp from right",
"       </td>",
"       <td>",
"        Puncture of carotid relatively common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Easy to cannulate",
"       </td>",
"       <td>",
"        Risk of pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Subclavian",
"       </td>",
"       <td rowspan=\"2\">",
"        15 to 20",
"       </td>",
"       <td rowspan=\"2\">",
"        30",
"       </td>",
"       <td rowspan=\"2\">",
"        40",
"       </td>",
"       <td>",
"        Easy to float, esp from left",
"       </td>",
"       <td rowspan=\"2\">",
"        Higher risk of pneumothorax than with IJ approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Easy to cannulate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Femoral",
"       </td>",
"       <td rowspan=\"4\">",
"        45",
"       </td>",
"       <td rowspan=\"4\">",
"        55",
"       </td>",
"       <td rowspan=\"4\">",
"        65",
"       </td>",
"       <td>",
"        Easy to cannulate",
"       </td>",
"       <td rowspan=\"4\">",
"        More difficult to float catheter (may require fluoroscopy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fewer major complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Higher risk of infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of DVT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"6\">",
"        Brachial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right",
"       </td>",
"       <td class=\"sublist_other\">",
"        40",
"       </td>",
"       <td class=\"sublist_other\">",
"        50",
"       </td>",
"       <td class=\"sublist_other\">",
"        60",
"       </td>",
"       <td class=\"sublist_other\">",
"        Few major complications",
"       </td>",
"       <td class=\"sublist_other\">",
"        More time-consuming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"3\">",
"        Left",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        50",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        60",
"       </td>",
"       <td class=\"sublist_other\" rowspan=\"3\">",
"        70",
"       </td>",
"       <td class=\"sublist_other\">",
"        Safer if bleeding diathesis or coagulopathy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Difficult to float catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\" rowspan=\"2\">",
"        May be easiest in morbidly obese patients",
"       </td>",
"       <td class=\"sublist_other\">",
"        Lower rate of successful cannulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Limited to 72 hour duration due to phlebitis and infection risk",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36060=[""].join("\n");
var outline_f35_13_36060=null;
var title_f35_13_36061="TNM staging testicular CA";
var content_f35_13_36061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for testicular cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Primary tumor (T)*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pTX",
"       </td>",
"       <td>",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT0",
"       </td>",
"       <td>",
"        No evidence of primary tumor (eg, histologic scar in testis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pTis",
"       </td>",
"       <td>",
"        Intratubular germ cell neoplasia (carcinoma in situ)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT1",
"       </td>",
"       <td>",
"        Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT2",
"       </td>",
"       <td>",
"        Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT3",
"       </td>",
"       <td>",
"        Tumor invades the spermatic cord with or without vascular/lymphatic invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pT4",
"       </td>",
"       <td>",
"        Tumor invades the scrotum with or without vascular/lymphatic invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Clinical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NX",
"       </td>",
"       <td>",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        N0",
"       </td>",
"       <td>",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        N1",
"       </td>",
"       <td>",
"        Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        N2",
"       </td>",
"       <td>",
"        Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        N3",
"       </td>",
"       <td>",
"        Metastasis with a lymph node mass more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Pathologic (pN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        pNX",
"       </td>",
"       <td>",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        pN0",
"       </td>",
"       <td>",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        pN1",
"       </td>",
"       <td>",
"        Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to five nodes positive, none more than 2 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        pN2",
"       </td>",
"       <td>",
"        Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than five nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        pN3",
"       </td>",
"       <td>",
"        Metastasis with a lymph node mass more than 5 cm in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        M1",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1a",
"       </td>",
"       <td class=\"sublist_other\">",
"        Nonregional nodal or pulmonary metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M1b",
"       </td>",
"       <td class=\"sublist_other\">",
"        Distant metastasis other than to nonregional lymph nodes and lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Serum tumor markers (S)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SX",
"       </td>",
"       <td>",
"        Marker studies not available or not performed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S0",
"       </td>",
"       <td>",
"        Marker study levels within normal limits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S1",
"       </td>",
"       <td>",
"        LDH &lt;1.5 x Nl",
"        <sup>",
"         &loz;",
"        </sup>",
"        <strong>",
"         and",
"        </strong>",
"        hCG (mIu/mL) &lt;5000",
"        <strong>",
"         and",
"        </strong>",
"        AFP (ng/mL) &lt;1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S2",
"       </td>",
"       <td>",
"        LDH 1.5-10 x Nl",
"        <strong>",
"         or",
"        </strong>",
"        hCG (mIu/mL) 5000-50,000",
"        <strong>",
"         or",
"        </strong>",
"        AFP (ng/mL) 1000-10,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S3",
"       </td>",
"       <td>",
"        LDH &gt;10 x Nl",
"        <strong>",
"         or",
"        </strong>",
"        hCG (mIu/mL) &gt;50,000",
"        <strong>",
"         or",
"        </strong>",
"        AFP (ng/mL) &gt;10,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The extent of primary tumor is usually classified after radical orchiectomy, and for this reason, a",
"     <em>",
"      pathologic",
"     </em>",
"     stage is assigned.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Except for pTis and pT4, extent of primary tumor is classified by radical orchiectomy. TX may be used for other categories in the absence of radical orchiectomy.",
"      <br>",
"       &Delta; Required for staging.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Nl indicates the upper limit of normal for the LDH assay.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36061=[""].join("\n");
var outline_f35_13_36061=null;
var title_f35_13_36062="Exercise thallium predictors";
var content_f35_13_36062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Predictors of outcome from exercise thallium stress tests",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 451px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier analysis of data from 3400 patients undergoing exercise thallium stress testing. The exercise workload in METs (top panel) and the thallium score (bottom panel) were independent predictors of all-cause mortality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Snader, CE, Marwick, TH, Pashkow, FJ, et al, J Am Coll Cardiol 1997; 30:641.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36062=[""].join("\n");
var outline_f35_13_36062=null;
var title_f35_13_36063="Four flap z-plasty";
var content_f35_13_36063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Four flap Z-plasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A four flap Z-plasty has two additional limbs (forming A and D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_13_36063=[""].join("\n");
var outline_f35_13_36063=null;
